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Abstract
We introduce a novel Bayesian hybrid matrix
factorisation model (HMF) for data integra-
tion, based on combining multiple matrix fac-
torisation methods, that can be used for in-
and out-of-matrix prediction of missing val-
ues. The model is very general and can be
used to integrate many datasets across dif-
ferent entity types, including repeated exper-
iments, similarity matrices, and very sparse
datasets. We apply our method on two bio-
logical applications, and extensively compare
it to state-of-the-art machine learning and
matrix factorisation models. For in-matrix
predictions on drug sensitivity datasets we
obtain consistently better performances than
existing methods. This is especially the case
when we increase the sparsity of the datasets.
Furthermore, we perform out-of-matrix pre-
dictions on methylation and gene expression
datasets, and obtain the best results on two
of the three datasets, especially when the pre-
dictivity of datasets is high.
1 INTRODUCTION
Matrix factorisation methods offer an elegant way of
analysing datasets. Here, a matrix relating two en-
tity types is decomposed into two smaller matrices
(so-called latent factors) so that their product approxi-
mates the original one. This extracts hidden structure
in the data, and allows the prediction of missing val-
ues. Non-negativity constraints are often imposed on
the matrices (Lee and Seung [1999]) as this makes the
results easier to interpret, and it is often inherent to
the problem – such as in image processing (Lee and
Seung [1999]) or bioinformatics (Brunet et al. [2004]).
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Non-negative matrix tri-factorisation is an extension of
these methods, first introduced by Ding et al. [2006],
where the matrix is decomposed into three smaller ma-
trices, which again are constrained to be non-negative.
Both methods are shown in Figure 1.
A key question is how to best predict missing values
in these datasets. There are two different settings for
this problem. Firstly, in-matrix predictions, where
if we are trying to predict an unknown value for a pair
of drug D1 and cancer type C1, we will have at least
one known value for D1 with another cancer type C2,
and for C1 with another drug D1. The other setting is
out-of-matrix predictions, where we predict values
for entirely unseen rows or columns, such as a new
drug for which we have no observed values inside the
matrix. This is illustrated in Figure 1.
In practice we often have many different datasets,
relating different entity types. Matrix factorisation
methods can be effectively used for data integration,
by jointly decomposing multiple datasets and sharing
the latent matrices (Zhang et al. [2005]). This can
improve our matrix factorisations, and hence our in-
matrix predictions, and also allows us to do out-of-
matrix predictions. Another approach, based on mul-
tiple matrix tri-factorisation, was introduced by Wang
et al. [2008], where they shared two of the three la-
tent matrices. By sharing more factors than the mul-
tiple matrix factorisation method, and hence having a
much smaller dataset-specific matrix in the middle, we
can more effectively integrate similar datasets. This is
particularly interesting for integrating repeated exper-
iments, where different biological labs perform simi-
lar experiments between the same two entity types,
such as gene expression profiles and methylation lev-
els. Both approaches are illustrated in Figure 2.
We propose a novel Bayesian model for data inte-
gration, which combines multiple matrix factorisa-
tion and tri-factorisation. Our method can integrate
many datasets across different entity types, including
repeated experiments, similarity matrices, and very
sparse datasets. In our method, the user can spec-
ify for each dataset whether it should be decomposed
into two matrices, in which case only the row factor
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Figure 1: Difference between in- and out-of-matrix predictions for missing values in matrices; and the
difference between matrix factorisation and matrix tri-factorisation.
≈
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Figure 2: Difference between multiple matrix fac-
torisation and multiple matrix tri-factorisation.
The shared factor matrices are highlighted in grey.
matrices are shared, or into three, in which case the
row and column matrices are shared. This gives a hy-
brid between matrix factorisation and tri-factorisation.
Additionally, the user can also specify for each of the
latent matrices whether the factors should be nonneg-
ative or real-valued, giving a hybrid between nonnega-
tive, semi-nonnegative, and real-valued factorisations.
By using a probabilistic approach, our method can ef-
fectively handle missing values and predict them, both
for in- and out-of-matrix predictions, and the Bayesian
approach is much less prone to overfitting than non-
probabilistic models. Furthermore, the rank of each
matrix is automatically chosen using Automatic Rele-
vance Determination, eliminating the need to perform
model selection. Related work is discussed in Section
4.
To demonstrate our method, we apply it to two dif-
ferent settings. Firstly, we consider four drug sensitiv-
ity datasets, where the matrices are similar and hence
have high predictivity. We measure the in-matrix pre-
dictive performance of our method, as well as Bayesian
and non-probabilistic matrix factorisation methods,
and several state-of-the-art machine learning methods.
Our model consistently outperforms all other methods,
especially when the sparsity of the data increases. Sec-
ondly, we integrate gene expression, promoter region
methylation, and gene body methylation profiles for
breast cancer patients. These datasets are much more
dissimilar, hence predicting one dataset given the oth-
ers is much harder. However, in out-of-matrix predic-
tion experiments our method achieves better perfor-
mance than state-of-the-art machine learning methods
on two of the three combinations.
2 MATRIX FACTORISATION
The problem of non-negative matrix factorisation
(NMF) can be formulated as decomposing a matrix
R ∈ RI×J into two latent (unobserved) factor matri-
ces F ∈ RI×K+ , G ∈ RJ×K+ . In other words, solv-
ing R = FGT + E, where noise is captured by ma-
trix E ∈ RI×J . Some entries in the dataset R may
not be known – we represent the indices of observed
entries by the set Ω = {(i, j) | Rij observed}. Sim-
ilarly, non-negative matrix tri-factorisation (NMTF)
can be formulated as finding three latent factor ma-
trices F ∈ RI×K+ , S ∈ RK×L+ , G ∈ RJ×K+ , such that
R = FSGT +E.
Some NMF methods such as Lee and Seung [2001] rely
on optimisation-based techniques, where a cost func-
tion between the observed matrix R and the predicted
matrix FGT is minimised, like the mean squared error
or I-divergence, using multiplicative updates. Alter-
natively, probabilistic models formulate the problem of
NMF by treating the entries in F ,G as unobserved or
latent variables, and the entries in R as observed dat-
apoints. Bayesian approaches furthermore place prior
distributions over the latent variables. The problem
then involves finding the distribution over F ,G after
observing R, p(F ,G|R). This Bayesian approach has
several benefits: it is less prone to overfitting, espe-
cially on small or sparse datasets; a distribution over
the factors is obtained, rather than just a point esti-
mate; it allows for flexible and elegant models (such as
automatic model selection using Automatic Relevance
Determination); and missing entries are easily handled
(we simply do not include them in the observed data,
through the Ω set introduced earlier). However, find-
ing this posterior distribution can be very inefficient.
Schmidt et al. [2009] introduced a Bayesian model for
non-negative matrix factorisation, by using Exponen-
tial priors and a Gaussian likelihood. For the precision
τ of the likelihood they used a Gamma distribution
with shape α > 0 and rate β > 0. The full set of
parameters for this model is denoted θ = {F ,G, τ}.
Rij ∼ N (Rij |F i ·Gj , τ−1)
Fik ∼ E(Fik|λF ) Gjk ∼ E(Gjk|λG) τ ∼ G(τ |α, β)
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Inference to find the posterior p(F ,G|R) can be effi-
ciently performed using Gibbs sampling. This method
works by sampling new values for each parameter θi
from its marginal p(θi|θ−i, D) given the current values
of the other parameters θ−i, and the observed data
D. If we sample new values in turn for each param-
eter θi from p(θi|θ−i, D), we will eventually converge
to draws from the posterior p(θ|D), which can be used
to approximate it. When doing so we have to discard
the first n draws because it takes a while to converge
(burn-in), and since consecutive draws are correlated
we only use every ith value (thinning).
For this model we draw from the following distribu-
tions:
p(Fik|τ,F−ik,G, D) p(Gjk|τ,F ,G−jk, D)
p(τ |F ,G, D)
where F−ik denotes all elements in F except Fik, and
similarly for G−jl. Using Bayes’ theorem we obtain
the following posterior distributions:
p(τ |F ,G, D) = G(τ |α∗, β∗)
p(Fik|τ,F−ik,G, D) = T N (Fik|µFik, τFik)
p(Gjl|τ,F ,G−jk, D) = T N (Gjk|µGjl, τGjk),
where
T N (x|µ, τ) =

√
τ
2pi exp
{− τ2 (x− µ)2}
1− Φ(−µ√τ) if x ≥ 0
0 if x < 0
is a truncated normal: a normal distribution with zero
density below x = 0 and renormalised to integrate to
one. Φ(·) is the cumulative distribution function of
N (0, 1).
The extension of this model to non-negative matrix tri-
factorisation is straightforward. We can also choose to
remove the nonnegativity constraint, by instead using
a Gaussian prior for the factor matrices. This results in
a Gaussian posterior in the Gibbs sampling algorithm,
with slightly different parameters. A semi-nonnegative
model, with only one real-valued matrix (G for MF,
and S for MTF), is illustrated below. Gibbs samplers
for all mentioned models are given in the Supplemen-
tary Materials (Section 1).
Prior: Posterior:
Fik ∼ E(Fik|λF ) Fik ∼ T N (Fik|µFik, τFik)
Gjk ∼ N (Gjk|0, λ−1G ) Gjk ∼ N (Gjk|µGjk, (τGjk)−1)
3 HYBRID MATRIX
FACTORISATION
The idea behind Hybrid Matrix Factorisation (HMF)
is to integrate multiple datasets by jointly decompos-
ing them, and sharing their latent factors. Formally,
2) Dl = F tl(Gl)T Etl
Features
≈
1) Rn = F tnSn(F un)T Etn
Eun
≈
3) Cm = F tmSm(F tm)T Etm
Etm
≈ ∗ ∗
Figure 3: The three different types of datasets and
factorisations. Shared factor matrices are grey, and
dataset-specific ones are white. The two grey matri-
ces for the third factorisation type are the same (*).
we are given a number of datasets spanning T different
entity types E1, .., ET . Each entity type Et has It in-
stances, Kt factors, and a factor matrix F
t ∈ RIt×Kt ,
which is shared across the matrix factorisations of
datasets that relate this entity type. We consider three
dataset types, which we decompose in different ways
(see Figure 3):
1. Main datasets R = {R1, ..,RN}, relating two en-
tity types, both of which we have other datasets
for (such as features or repeated experiments).
Each dataset Rn ∈ RItn×Iun relates entity types
Etn , Eun . We use matrix tri-factorisation to de-
compose it into two entity type factor matrices
F tn ,F un , and a dataset-specific matrix Sn ∈
RKtn×Kun .
2. Feature datasets D = {D1, ..,DL}, giving fea-
ture values for an entity type. Each dataset
Dl ∈ RItl×Jl relates an entity type Etl to Jl fea-
tures. We use matrix factorisation to decompose
it into one entity type factor matrix F tl , and a
dataset-specific matrix Gl ∈ RJl×Ktl .
3. Similarity datasets C = {C1, ..,CM}, giving sim-
ilarities between entities of the same entity type
(such as Jaccard kernels). Each dataset Cm ∈
RItm×Itm relates an entity type Etm to itself. We
use matrix tri-factorisation to decompose it into a
entity type factor matrix F tm , a dataset-specific
matrix Sm ∈ RKtm×Ktm , and F tm again.
Rn = F tnSn(F un)T +En
Dl = F tl(Gl)T +El
Cm = F tmSm(F tm)T +Em
The above formulation allows the user to very easily
choose the kind of joint factorisation. By passing a set
Bayesian Hybrid Matrix Factorisation for Data Integration
of matrices as D1, .., DL, multiple matrix factorisation
is performed. Instead, passing them as R1, .., RN gives
multiple matrix tri-factorisation. A hybrid combina-
tion is also possible, as illustrated in Figure 4. Further-
more, each of the factor matrices can either be non-
negative (using an exponential prior), or real-valued
(using a Gaussian prior), additionally giving a hybrid
of nonnegative, semi-nonnegative and real-valued ma-
trix factorisation. The model likelihood functions are
Rnij ∼ N (Rnij |F tni · Sn · F unj , (τn)−1)
Dmij ∼ N (Dlij |F tli ·Glj , (τ l)−1)
Cmij ∼ N (Cmij |F tmi · Sm · F tmj , (τm)−1),
with Bayesian priors
τn, τ l, τm ∼ G(τ∗|ατ , βτ )
F tik ∼ E(F tik|λtk) or F tik ∼ N (F tik|0, (λtk)−1)
Gljk ∼ E(Gljl|λtlk ) or Gljk ∼ N (Gljl|0, (λtlk )−1)
Snkl ∼ E(Snkl|λnS) or Snkl ∼ N (Snkl|0, (λnS)−1)
Smkl ∼ E(Smkl |λmS ) or Smkl ∼ N (Smkl |0, (λmS )−1).
Automatic Relevance Determination (ARD)
We employ a Bayesian ARD prior, which helps per-
form automatic model selection. Note the λtk param-
eters in the prior of F tik and G
l
jk. This parameter is
shared by all entities of type Et, and hence the entire
factor k is either activated (if λtk has a low value) or
“turned off” (if λtk has a high value). The ARD works
by placing a Gamma prior over each of these variables,
λtk ∼ G(λtk|α0, β0).
Through this construction, factors that are active for
only a few entities will be pushed further to zero, turn-
ing the factor off. This prior has been used extensively
for model selection in Virtanen et al. [2011, 2012] for
real-valued matrix factorisation, and Tan and Fe´votte
[2013] for nonnegative matrix factorisation. Instead of
having to choose the correct values for the Kt, we can
give an upper bound and our model will automatically
determine the number of factors to use.
Dataset importance One challenge with multiple
matrix factorisation is that it relies on finding common
patterns in multiple datasets. If two datasets are very
different, the methods may end up finding a solution
that fits one dataset much better, resulting in poor pre-
dictions for the other one. To address this, we add an
importance value for each of the Rn,Dl,Cm datasets,
respectively αn, αl, αm, to ensure that the method will
converge to a solution that better fits datasets with
higher importance values. We modify the likelihood
Repeated experiments
≈
Row feature datasets
≈
Column feature datasets
≈
Figure 4: Overview of HMF, combining the multiple
matrix tri-factorisation of two repeated experiments
with multiple matrix factorisations of row and column
feature datasets. Shared factor matrices are grey.
of the model by using these importance values,
p(θ|R,D,C) ∝ p(θ)×
N∏
n=1
p(Rn|F tn ,Sn,F un , τn)αn
×
L∏
l=1
p(Dl|F tl ,Gl, τ l)αl ×
M∏
m=1
p(Cm|F tm ,Sm, τm)αm
where θ is the set of model parameters. This tech-
nique was used by Remes et al. [2015] to ensure their
model fits the binary training labels. This technique
can be interpreted as repeating each of the values in
the dataset Dl αl times, hence forcing the model to fit
better to that dataset.
Inference An efficient Gibbs sampling algorithm
can be used for inference due to the model’s conjugacy.
For details see Supplementary Materials (Section 1).
4 RELATED WORK
The idea of using matrix factorisation and tri-
factorisation to integrate multiple datasets can be
traced back to the CANDECOMP/PARAFAC (CP)
and PARAFAC2 tensor decompositions (Harshman
[1970, 1972]). These models are in fact a less gen-
eral version of multiple matrix tri-factorisation. If we
are given multiple datasets for the same two entity
types and concatenate them to form a tensor, the CP
method will perform multiple matrix tri-factorisation,
where the dataset-specific middle matrices S are re-
stricted to being diagonal.
Multiple matrix factorisation models for integrating
datasets between two entity types (such as multiple
gene expression profiles), by sharing one of the two
factor matrices, can be found amongst others in Zhang
et al. [2005] and Lee et al. [2012], with Bayesian mod-
els given by Virtanen et al. [2012] and Chatzis [2014].
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Some approaches focus on jointly decomposing two
datasets spanning three entity types and sharing two
latent matrices (Shi et al. [2010]), sometimes using su-
pervised labels for learning (Zhu et al. [2007]). Others
do not explicitly share the latent matrices but instead
add a penalisation term based on the consensus be-
tween the matrices (Seichepine et al. [2013]).
More general matrix factorisation methods are pre-
sented by Lippert et al. [2008] and Singh and Gor-
don [2008], where each entity type has its own la-
tent matrix, with a Bayesian version given in Klami
et al. [2014]. However, these approaches cannot inte-
grate multiple datasets between the same two entity
types, since all matrices are shared. We would require
a third, dataset-specific matrix to solve this problem
– which is exactly what matrix tri-factorisation allows
us to do. Models for multiple non-negative matrix tri-
factorisation are given by Wang et al. [2008] and Zˇitnik
and Zupan [2015], which can also handle constraint
matrices, but require all given datasets to be fully ob-
served. As a result, missing values inside each matrix
need to be imputed. For binary datasets a missing
association can easily be imputed as a zero, but for
real-valued datasets this is not a viable option.
Overall, our method is novel in several aspects. Firstly,
it is the first general hybrid model between matrix fac-
torisation and tri-factorisation. A non-probabilistic
version can be found in Zhu et al. [2007], but this
model only combined a single matrix tri-factorisation
with a single matrix factorisation. Secondly, our model
is a hybrid between nonnegative and real-valued fac-
tors. If multiple datasets are jointly decomposed, one
can be a nonnegative matrix factorisation, where an-
other can be semi-nonnegative, and another can be
real-valued. Finally, through formulating the method
as a Bayesian probabilistic model, it can deal with
missing values, perform automatic model selection,
and is much less prone to overfitting (especially for
sparse datasets).
In this paper we are demonstrating our method on two
specific biological datasets. However, it can be widely
applied to other biological applications such as pre-
dicting drug-target interactions (Go¨nen [2012]) or gene
functions (Lippert et al. [2008]), as well as other fields
like collaborative filtering (Salakhutdinov and Mnih
[2008]) and image analysis (Zhang et al. [2005]).
5 DATASETS
To demonstrate the advantages of our approach for
missing values prediction, we consider two different
applications. Firstly, integrating four drug sensitiv-
ity datasets, where the datasets are similar and hence
predictivity of the datasets is high. Here we perform
in-matrix predictions of missing values. Secondly, inte-
grating gene expression and methylation level datasets
for breast cancer patients and cancer driver genes,
where the datasets are much more dissimilar. We per-
form out-of-matrix predictions, using the methylation
levels of patients to predict gene expression values, and
vice versa. We briefly introduce the datasets below; a
more thorough description of the datasets can be found
in the Supplementary Materials (Section 3).
5.1 Drug Sensitivity Data
We consider four different drug sensitivity datasets,
containing 650 unique drugs and 1209 cell lines. Each
of these datasets shows the response (sensitivity) of
a given cell line (cancer type in a tissue) to a given
drug, either measuring the drug concentration needed
to inhibit undesired cell line activity by half (IC50), or
the drug concentration that achieves half the maximal
desired effect on the cell line (EC50).
• Genomics of Drug Sensitivity in Cancer (GDSC
v5.0, Yang et al. [2013]). Natural log of IC50 val-
ues for 139 drugs across 707 cell lines, with 80%
observed entries.
• Cancer Therapeutics Response Portal (CTRP v2,
Seashore-Ludlow et al. [2015]). EC50 values for
545 drugs across 887 cell lines, with 80% observed
entries.
• Cancer Cell Line Encyclopedia (CCLE, Barretina
et al. [2012]). Both IC50 and EC50 values for
24 drugs across 504 cell lines, with 96% and 63%
observed entries, respectively.
We selected the drugs and cell lines that are present
in at least two of the four datasets, and for which we
had side information like gene expression profiles avail-
able. This resulted in a lot of drugs and cell lines be-
ing filtered. For the GDSC dataset we undid the log
transform. We rescaled the values per cell line to the
range [0,1] in each dataset. We used the cell line fea-
tures provided by the GDSC dataset (gene expression
levels, copy number variations, and mutation infor-
mation), and for the drugs we extracted 1D and 2D
descriptors and structural fingerprints. We obtained
primary protein targets from GDSC for 48 of the 52
drugs.
After preprocessing and filtering, the four datasets
span 52 unique drugs and 399 cell lines, with 95.1%
of the entries having at least one observed value, and
62.9% of the entries having at least two observed val-
ues. The information on the four datasets is sum-
marised in Table 1, along with the fraction of over-
lapping observed entries.
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Table 1: Overview of the four drug sensitivity dataset after preprocessing and filtering.
Number Number Fraction Overlap with other datasets
Dataset cell lines drugs observed GDSC IC50 CTRP EC50 CCLE IC50 CCLE EC50
GDSC IC50 399 48 73.57% - 52.25% 9.34% 6.00%
CTRP EC50 379 46 86.03% 57.39% - 11.96% 7.37%
CCLE IC50 253 16 96.42% 44.19% 51.51% - 55.06%
CCLE EC50 252 16 58.88% 28.52% 31.87% 55.28% -
5.2 Methylation and Gene Expression Data
Our second application is that of integrating promoter-
region methylation (PM) and gene body methylation
(GM) datasets with a gene expression (GE) profile
for breast cancer patients, coming from the The Can-
cer Genome Atlas (TCGA, Koboldt et al. [2012]).
There are 254 different samples (both healthy and tu-
mor tissues), across 13966 genes. We focus on 160
breast cancer driver genes, from the IntOGen database
(Gonzalez-Perez et al. [2013]). We standardise the
datasets to have zero mean and unit standard devi-
ation per gene. Note that this dataset is not nonneg-
ative. In our experiments we predict values in one of
the three datasets, given the values of the other two.
6 IN-MATRIX PREDICTIONS
We performed 10-fold cross-validation on each of the
four drug sensitivity datasets to predict missing values.
We tested two variants of our HMF model: multiple
matrix tri-factorisation using all four drug sensitivity
datasets (HMF D-MTF,Rn), and multiple matrix fac-
torisation on all four drug sensitivity datasets, sharing
the cell line factors (HMF D-MF, Dl).
We compared our model to several state of the art
methods. Since the four datasets are all nonnegative,
we can use nonnegative matrix factorisation (NMF)
and tri-factorisation (NMTF) models. We compare
with non-probabilistic NMF by Lee and Seung [2001]
(NP-NMF), Bayesian NMF by Schmidt et al. [2009]
(BNMF), non-probabilistic NMTF by Yoo and Choi
[2009] (NP-NMTF), Bayesian NMTF (BNMTF), and
Multiple NMF (sharing the cell line factors). We
also applied several state-of-the-art machine learning
models using the skikit-learn Python package, par-
ticularly: Linear Regression (LR), Random Forests
(RF, 100 trees), and Support Vector Regression (SVR,
rbf kernel). These methods were given the drug and
cell line features for training. Finally, we used a
method called Kernelised Bayesian Matrix Factorisa-
tion (KBMF, Go¨nen and Kaski [2014]), which was used
by Ammad-ud din et al. [2014] to predict drug sensitiv-
ity values for the GDSC dataset. This method lever-
ages similarity kernels of the drugs and cell lines, which
we reconstructed for the feature datasets (Jaccard ker-
nel for binary features, Gaussian for real-valued fea-
tures after standardising each feature).
We performed nested cross-validation to select the
dimensionality K for the matrix factorisation mod-
els and KBMF. In contrast, our model simply used
Kt = 10 for each entity type Et, and let the ARD
choose the correct number of factors. We used nonneg-
ative factors for the entity type factor matrices (F t),
and real-valued for all other factors. We used K-means
and least squares initialisation, and set all importance
values to one.
The results for cross-validation are given in Table 2.
We see that our HMF models outperform all other
methods, giving predictive gains of up to 30%. The
multiple matrix tri-factorisation approach (HMF D-
MTF) achieves the best performance on three of the
datasets, and is a close second on the fourth. We also
see that the Bayesian matrix factorisation models out-
perform both the non-probabilistic approaches, and
the state-of-the-art machine learning methods, demon-
strating that Bayesian matrix factorisation is a power-
ful paradigm for in-matrix predictions, with our pro-
posed HMF model giving significant gains in predictive
performance.
7 SPARSE DATA PREDICTIONS
A very important use case is when there are few ob-
served entries, leading to a sparse matrix. We mea-
sured the performances of in-matrix predictions on
sparse matrices, focusing on the GDSC and CTRP
drug sensitivity datasets as these are the largest.
We vary the fraction of missing values and predict
those entries, taking the average of twenty random
training-test data splits per fraction. We compared
our model’s multiple matrix factorisation and tri-
factorisation models (HMF D-MF and HMF D-MTF)
with the other matrix factorisation models (NMF,
NMTF, BNMF, BNMTF). For the dimensionality of
HMF we use Kt = 10 as before, and for the matrix
factorisation models we use the most common dimen-
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Table 2: Mean squared error (MSE) of 10-fold in-matrix cross-validation results on the drug sensitivity datasets.
We also give the relative improvement (% impr.) compared to NMF. The best performances are highlighted in
bold.
GDSC IC50 CTRP EC50 CCLE IC50 CCLE EC50
Method MSE % impr. MSE % impr. MSE % impr. MSE % impr.
NMF 0.0896 - 0.0959 - 0.0746 - 0.1535 -
NMTF 0.0879 1.91% 0.0954 0.44% 0.0747 -0.18% 0.1506 1.91%
Multiple NMF 0.0859 4.10% 0.0928 3.18% 0.0666 10.64% 0.1157 24.66%
BNMF 0.0805 10.20% 0.0919 4.05% 0.0594 20.29% 0.1318 14.19%
BNMTF 0.0799 10.81% 0.0920 4.03% 0.0593 20.52% 0.1292 15.84%
KBMF 0.0819 8.60% 0.0919 4.13% 0.0618 17.13% 0.1303 15.13%
LR 0.0886 1.10% 0.0949 1.00% 0.0719 3.62% 0.1342 12.60%
RF 0.0876 2.21% 0.0989 -3.15% 0.0668 10.47% 0.1219 20.62%
SVR 0.1091 -21.72% 0.1091 -13.80% 0.0916 -22.76% 0.1230 19.92%
HMF D-MF 0.0775 13.54% 0.0919 4.11% 0.0592 20.65% 0.1062 30.81%
HMF D-MTF 0.0768 14.25% 0.0908 5.28% 0.0558 25.17% 0.1073 30.12%
sionality used in the cross-validation from Section 6.1
Figure 5 shows that the non-probabilistic models start
overfitting very quickly as the sparsity levels of two
datasets increase, on both the GDSC (5a) and CTRP
(5b) datasets. The Bayesian versions perform lot bet-
ter, but our HMF models consistently outperform all
other models, even when only 10% of the values are
observed. The multiple matrix tri-factorisation model
(HMF D-MTF) performs particularly well.
8 OUT-OF-MATRIX PREDICTIONS
We did three out-of-matrix prediction experiments on
the methylation and gene expression data. We per-
formed ten-fold cross-validation, splitting the 254 sam-
ples into ten folds. We predicted the gene expression
values for new samples, given the gene expression val-
ues of the other samples and both of the methylation
datasets (PM, GM to GE). We also did this for the
other two combinations (GE, GM to PM; GE, PM
to GM). Methylation data is known to be correlated
with gene expression values (Kundaje et al. [2015]),
although this correlation is generally weak. We there-
fore expected a weak predictive performance, but it is
interesting to see which methods perform best.
We used the HMF D-MF and HMF D-MTF models
described earlier. We also considered the similarity
dataset part of our model (Cm) by constructing a sim-
ilarity kernel for the samples using each of the datasets
(see Supplementary Materials, Section 3.4). We give
the model the dataset we are trying to predict (e.g.
1GDSC: K = 2, (K,L) = (4, 4), K = 4, (K,L) = (7, 7).
CTRP: K = 2, (K,L) = (2, 4), K = 3, (K,L) = (3, 3).
GE), decomposing it using matrix factorisation, and
also give it the similarity kernels for the other two
(e.g. GM and PM). We call this approach HMF S-
MF. We could have also used matrix tri-factorisation,
but since the third matrix is not shared this is effec-
tively the same model.
For the HMF D-MF models we used Kt = 40, 0.5 as
the importance value for the dataset we are trying to
predict, and 1.5 for the other two. For HMF D-MTF
we used Kt = 40, and 0.5 as importance for all three
datasets. Finally, for HMF S-MF we used Kt = 30,
and 1.0 as importance for all three datasets. For all
three, we used nonnegative factors for shared matri-
ces (K-means initialisation), and real-valued ones for
private matrices (least squares initialisation).
We compared with the LR, RF, and SVR algorithms,
giving two datasets as features, and the third as regres-
sion values. We used the gene average as a baseline.
Since the datasets are real-valued, we cannot compare
with any nonnegative matrix factorisation models.
The results for this out-of-matrix cross-validation are
given in Table 3. The HMF D-MF model outper-
forms all state-of-the-art machine learning methods
on two of the three datasets, and is only beaten by
SVR on the first one. Our model performs especially
well on the third case (GE, PM to GM), implying our
method works best when the predictivity of values is
high (lower MSE). The HMF D-MTF and HMF S-MF
methods perform slightly worse, but are still competi-
tive with the other machine learning methods.
Many of the model choices in the experiments (such as
model selection, initialisation, factorisation and nega-
Bayesian Hybrid Matrix Factorisation for Data Integration
(a) GDSC (b) CTRP
Figure 5: Graphs showing average mean squared error (MSE) and standard deviation of in-matrix predictions on
the GDSC (left) and CTRP (right) drug sensitivity datasets. We vary the fraction of missing entries, averaging
performance across 20 random splits between train and test data, and compare our HMF models (HMF D-MF,
HMF D-MTF) with several matrix factorisation models (NMF, NMTF, BNMF, BNMTF).
Table 3: Mean squared error (MSE) of 10-fold out-of-
matrix cross-validation results on the promoter-region
methylation (PM), gene body methylation (GM), and
gene expression (GE) datasets. We use two datasets
as features, and predict values for new samples in the
third dataset. The best results are highlighted in bold.
GM, PM GE, GM GE, PM
Method to GE to PM to GM
Gene average 1.009 1.008 1.009
LR 2.847 2.036 1.478
RF 0.811 0.799 0.714
SVR 0.767 0.749 0.657
HMF D-MF 0.788 0.735 0.602
HMF D-MTF 0.850 0.798 0.640
HMF S-MF 0.820 0.794 0.672
tivity choices, and importance values) are explored ex-
tensively in Section 4 of the Supplementary Materials.
9 CONCLUSION
We have presented a fully Bayesian model for data
integration, based on a hybrid of nonnegative, semi-
nonnegative, and real-valued matrix factorisation and
tri-factorisation models. The general nature of this
model allows it to easily integrate many datasets across
different entity types, including repeated experiments,
similarity matrices, and very sparse datasets.
We demonstrated the model on two different biological
applications. On four drug sensitivity datasets we ob-
tained significant in-matrix prediction improvements
compared to state-of-the-art matrix factorisation and
machine learning methods. Our data fusion approach
based on multiple matrix tri-factorisation (HMF D-
MTF) is particularly powerful, achieving the best per-
formance on three of the four datasets. We also show
that our proposed model can provide consistently bet-
ter predictions on very sparse datasets, outperforming
all other matrix factorisation models. Finally, we inte-
grated methylation and gene expression data in an out-
of-matrix prediction setting, and here the approach
based on multiple matrix factorisation (HMF D-MF)
proved to be very powerful, beating all state-of-the-art
machine learning methods on two of the three datasets.
The approaches using multiple matrix tri-factorisation
and similarity datasets are also promising.
We showcased our model on different biological
datasets, but we believe that this is a powerful and
general framework that can also be applied to many
other fields.
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1 Models
In the model for Hybrid Matrix Factorisation (HMF), we combine models for Bayesian ma-
trix factorisation, tri-factorisation, and tri-factorisation of similarity kernels. For each model,
there are three versions: nonnegative, semi-nonnegative, and real-valued. In this section, we
give the details for each of these nine models, as well as the Gibbs sampling algorithms.
In addition, for the semi-nonnegative and real-valued versions we can either use a univariate
Gaussian (resulting in individual draws, but those can be drawn in parallel per column),
or a multivariate Gaussian as the posterior (resulting in row-wise draws of new values, but
each row can be drawn in parallel at the same time). We give Gibbs sampling algorithms for
both options. For the nonnegative models, where the posterior is a truncated normal, this is
technically also possible. However, we did not succeed in finding an efficiently implemented
library for multivariate truncated normal draws, and therefore do not support it.
We first introduce each of the models separately in Section 1.1, extending them with Au-
tomatic Relevance Determination in Section 1.2, and finally explain how we combine them
into one to form the HMF model in Section 1.3.
1.1 Matrix factorisation models
The matrix factorisation models are:
• Bayesian matrix factorisation (BMF), nonnegative matrix factorisation (BNMF), semi-
nonnegative matrix factorisation (BSNMF). We decompose D ≈ F ·GT . The Gibbs
samplers are given in Table 2.
• Bayesian matrix tri-factorisation (BMTF), nonnegative matrix tri-factorisation (BN-
MTF), and semi-nonnegative matrix tri-factorisation (BSNMTF). We decompose R ≈
F · S ·GT . The Gibbs samplers are given Table 3.
• Bayesian similarity matrix tri-factorisation (BSMTF), nonnegative similarity matrix
tri-factorisation (BNSMTF), and semi-nonnegative similarity matrix tri-factorisation
(BSNSMTF). We decompose C ≈ F ·S ·F T . The Gibbs sampler are given in Table 4.
The model priors and Gibbs sampling posteriors are given Table 1. Here,
• R,D,C ∈ RI×J , with i = 1..I, j = 1..J .
• F ∈ RI×K , with i = 1..I, k = 1..K.
• S ∈ RK×L (matrix tri-factorisation), or S ∈ RK×K (similarity matrix tri-factorisation),
with k = 1..K, l = 1..L.
• G ∈ RJ×K (matrix factorisation), orG ∈ RJ×L (matrix tri-factorisation), with j = 1..J ,
k = 1..K, l = 1..L.
• N (x|µ,Σ) is a multivariate Gaussian distribution with mean vector µ and covariance
matrix Σ.
2
Table 1: Model definitions, and Gibbs sampling posteriors.
Model name Likelihood Priors Posteriors Table
BMF Dij ∼ N (Dij |F i ·Gj , τ−1) Fik ∼ N (Fik|0, λ−1F ) N (Fik|µFik, (τFik)−1) 2
Gjk ∼ N (Gjk|0, λ−1G ) N (Gjk|µGjk, (τGjk)−1)
τ ∼ G(τ |α, β) G(τ |α∗, β∗)
BMF (multivariate) N (F i|µFi ,ΣFi ) 2
N (Gj |µGj ,ΣGj )
BNMF Dij ∼ N (Dij |F i ·Gj , τ−1) Fik ∼ E(Fik|λF ) T N (Fik|µFik, τFik) 2
Gjk ∼ E(Gjk|λG) T N (Gjk|µGjk, τGjk)
τ ∼ G(τ |α, β) G(τ |α∗, β∗)
BSNMF Dij ∼ N (Dij |F i ·Gj , τ−1) Fik ∼ E(Fik|λF ) T N (Fik|µFik, τFik) 2
Gjk ∼ N (Gjk|0, λ−1G ) N (Gjk|µGjk, (τGjk)−1)
τ ∼ G(τ |α, β) G(τ |α∗, β∗)
BSNMF (multivariate) N (Gj |µGj ,ΣGj ) 2
BMTF Rij ∼ N (Rij |F i · S ·Gj , τ−1) Fik ∼ N (Fik|0, λ−1F ) N (Fik|µFik, (τFik)−1) 3
Skl ∼ N (Skl|0, λ−1S ) N (Skl|µSkl, (τSkl)−1)
Gjl ∼ N (Gjl|0, λ−1G ) N (Gjl|µGjl, (τGjl )−1)
τ ∼ G(τ |α, β) G(τ |α∗, β∗)
BMTF (multivariate) N (F i|µFi ,ΣFi ) 3
N (Sk|µSk ,ΣSk )
N (Gj |µGj ,ΣGj )
BNMTF Rij ∼ N (Rij |F i · S ·Gj , τ−1) Fik ∼ E(Fik|λF ) T N (Fik|µFik, τFik) 3
Skl ∼ E(Skl|λS) T N (Skl|µSkl, τSkl)
Gjl ∼ E(Gjl|λG) T N (Gjl|µGjl, τGjl )
τ ∼ G(τ |α, β) G(τ |α∗, β∗)
BSNMTF Rij ∼ N (Rij |F i · S ·Gj , τ−1) Fik ∼ E(Fik|λF ) T N (Fik|µFik, τFik) 3
Skl ∼ N (Skl|0, λ−1S ) N (Skl|µSkl, (τSkl)−1)
Gjl ∼ E(Gjl|λG) T N (Gjl|µGjl, τGjl )
τ ∼ G(τ |α, β) G(τ |α∗, β∗)
BSNMTF (multivariate) N (Sk|µSk ,ΣSk ) 3
BSMTF Cij ∼ N (Cij |F i · S · F j , τ−1) Fik ∼ N (Fik|0, λ−1F ) N (Fik|µFik, (τFik)−1) 4
Skl ∼ N (Skl|0, λ−1S ) N (Skl|µSkl, (τSkl)−1)
τ ∼ G(τ |α, β) G(τ |α∗, β∗)
BSMTF (multivariate) N (F i|µFi ,ΣFi ) 4
N (Sk|µSk ,ΣSk )
BNSMTF Cij ∼ N (Cij |F i · S · F j , τ−1) Fik ∼ E(Fik|λF ) T N (Fik|µFik, τFik) 4
Skl ∼ E(Skl|λS) T N (Skl|µSkl, τSkl)
τ ∼ G(τ |α, β) G(τ |α∗, β∗)
BSNSMTF Cij ∼ N (Cij |F i · S · F j , τ−1) Fik ∼ E(Fik|λF ) T N (Fik|µFik, τFik) 4
Skl ∼ N (Skl|0, λ−1S ) N (Skl|µSkl, (τSkl)−1)
τ ∼ G(τ |α, β) G(τ |α∗, β∗)
BSNSMTF (multivariate) N (Sk|µSk ,ΣSk ) 4
3
The Gibbs sampling posteriors can be obtained using Bayes’ theorem, for example for BN-
MTF:
p(Fik|τ,F−ik,S,G,R, h)
∝ p(R|τ,F ,S,G)× p(Fik|λF )
∝
∏
j∈Ω1i
N (Rij|F i · S ·Gj, τ−1)× E(Fik|λF )
∝ exp
−τ2 ∑
j∈Ω1i
(Rij − F i · S ·Gj)2
× exp {−λFFik} × u(x)
∝ exp
−F 2ik2
τ ∑
j∈Ω1i
(Sk ·Gj)2

+Fik
−λF + τ ∑
j∈Ω1i
(Rij −
∑
k′ 6=k
Fik′(Sk′ ·Gj)) (Sk ·Gj)
× u(x)
∝ exp
{
−τ
F
ik
2
(Fik − µFik)2
}
× u(x)
∝ T N (Fik|µFik, τFik)
where h = {λF , λG, λS, α, β} are the hyperparameters to the model, u(x) is the unit step
function, and Ω1i = {j |(i, j) ∈ Ω}, Ω2j = {i |(i, j) ∈ Ω} indicate the observed entries per row
and column, respectively.
All the parameter values can be found in Tables 2-4. We use ⊗ to denote the outer product,
I for the identity matrix, and S·,l for the lth column of matrix S.
For the similarity matrix factorisation we could have also decided to decompose C = FF T +
E, without the intermediate matrix S. Ding et al. [2005] includes a good discussion of the
benefits to our approach. For this decomposition we do not consider diagonal entries of
C (in other words, (i, i) /∈ Ω, i = 1..I) as this leads to third and fourth order terms in
the posteriors and makes Gibbs sampling impossible. See Zhang and Yeung [2012] for a
non-probabilistic approach that does consider these elements, leading to a very complicated
optimisation problem.
4
Table 2: Gibbs Samplers for Bayesian Matrix Factorisation (BMF, BNMF, BSNMF).
PARAM UPDATE (GAUSSIAN PRIOR) UPDATE (EXPONENTIAL PRIOR)
α∗ α+
|Ω|
2
α+
|Ω|
2
β∗ β +
1
2
∑
(i,j)∈Ω
(Dij − F i ·Gj)2 β + 1
2
∑
(i,j)∈Ω
(Dij − F i ·Gj)2
τFik λF + τ
∑
j∈Ω1i
G2jk τ
∑
j∈Ω1i
G2jk
µFik
1
τFik
τ ∑
j∈Ω1i
(Dij −
∑
k′ 6=k
Fik′Gjk′)Gjk
 1
τFik
−λF + τ ∑
j∈Ω1i
(Dij −
∑
k′ 6=k
Fik′Gjk′)Gjk

τGjk λG + τ
∑
i∈Ω2j
F 2ik τ
∑
i∈Ω2j
F 2ik
µGjl
1
τGjl
τ ∑
i∈Ω2j
(Dij −
∑
k′ 6=k
Fik′Gjk′)Fik
 1
τGjl
−λG + τ ∑
i∈Ω2j
(Dij −
∑
k′ 6=k
Fik′Gjk′)Fik

ΣFi
λF I + τ ∑
j∈Ω1i
Gj ⊗Gj
−1 -
µFi Σ
F
i ·
τ ∑
j∈Ω1i
DijGj
 -
ΣGj
λGI + τ ∑
i∈Ω2j
F i ⊗ F i
−1 -
µGj Σ
G
j ·
τ ∑
i∈Ω2j
DijF i
 -
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+
τ
∑
(i
,j
)∈
Ω
F
2 ik
G
2 j
l
τ
∑
(i
,j
)∈
Ω
F
2 ik
G
2 j
l
µ
S k
l
1 τ
S k
l
  τ
∑
(i
,j
)∈
Ω
(R
ij
−
∑
(k
′ ,
l′
)6=
(k
,l
)
F
ik
′ S
k
′ l
′ G
j
l′
)F
ik
G
j
l 
1 τ
S k
l
  −λ
S
+
τ
∑
(i
,j
)∈
Ω
(R
ij
−
∑
(k
′ ,
l′
)6=
(k
,l
)
F
ik
′ S
k
′ l
′ G
j
l′
)F
ik
G
j
l 
τ
G j
l
λ
G
+
τ
∑ i∈Ω2 j
(F
i
·S
·,l
)2
τ
∑ i∈Ω2 j
(F
i
·S
·,l
)2
µ
G j
l
1 τ
G j
l
  τ∑ i
∈Ω
2 j
(R
ij
−
∑ l′ 6=lG
j
l′
(F
i
·S
·,l
′ )
)
(F
i
·S
·,l
) 
1 τ
G j
l
  −λ
G
+
τ
∑ i∈Ω2 j(
R
ij
−
∑ l′ 6=lG
j
l′
(F
i
·S
·,l
′ )
)
(F
i
·S
·,l
) 
Σ
F i
  λF
I
+
τ
∑ j∈Ω1 i
(S
·G
j
)
⊗
(S
·G
j
) −
1
-
µ
F i
Σ
F i
·  τ
∑ j∈Ω1 i
R
ij
(S
·G
j
) 
-
Σ
S k
  λS
I
+
τ
∑
(i
,j
)∈
Ω
F
ik
(G
j
⊗
G
j
) −
1
-
µ
S k
Σ
S k
·  τ
∑
(i
,j
)∈
Ω
(R
ij
−
∑ k′ 6=k
F
ik
′ (
S
k
′
·G
j
))
F
ik
G
j
 
-
Σ
G j
  λG
I
+
τ
∑ i∈Ω2 j(
F
i
·S
)
⊗
(F
i
·S
) −
1
-
µ
G j
Σ
G j
·  τ
∑ i∈Ω2 j
R
ij
(F
i
·S
) 
-
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∑
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′ (
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′ (
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·,l
))
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τ
S k
l
λ
S
+
τ
∑
(i
,j
)∈
Ω
F
2 ik
F
2 j
l
τ
∑
(i
,j
)∈
Ω
F
2 ik
F
2 j
l
µ
S k
l
1 τ
S k
l
  τ
∑
(i
,j
)∈
Ω
(C
ij
−
∑
(k
′ ,
l′
)6=
(k
,l
)
F
ik
′ S
k
′ l
′ F
j
l′
)F
ik
F
j
l 
1 τ
S k
l
  −λ
S
+
τ
∑
(i
,j
)∈
Ω
(C
ij
−
∑
(k
′ ,
l′
)6=
(k
,l
)
F
ik
′ S
k
′ l
′ F
j
l′
)F
ik
F
j
l 
Σ
F i
  λF
I
+
τ
 ∑ j∈Ω
1 i
(S
·F
j
)
⊗
(S
·F
j
)
+
∑ i′ ∈Ω2 i
(F
i′
·S
)
⊗
(F
i′
·S
)  
−
1
-
µ
F i
Σ
F i
·  τ
∑ j∈Ω1 i
C
ij
(S
·F
j
)
+
τ
∑ i′ ∈Ω2 i
C
i′
i(
F
i′
·S
) 
-
Σ
S k
  λS
I
+
τ
∑
(i
,j
)∈
Ω
F
ik
(F
j
⊗
F
j
) −
1
-
µ
S k
Σ
S k
·  τ
∑
(i
,j
)∈
Ω
(C
ij
−
∑ k′ 6=k
F
ik
′ (
S
k
′
·F
j
))
F
ik
F
j
 
-
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1.2 Matrix factorisation with ARD and importance values
We will now explain how to extend matrix factorisation with Automatic Relevance Deter-
mination (ARD) and importance values.
ARD We change the model definition to the following.
Dij ∼ N (Dij|F i ·Gj, τ−1)
Fik ∼ N (Fik|0, (λk)−1) or E(Fik|λk)
Gjk ∼ N (Gjk|0, (λk)−1) or E(Gjk|λk)
τ ∼ G(τ |α, β)
Notice that the main difference is replacing λF and λG by the parameter λk, for k = 1..K.
We place a Gamma prior over these variables,
λk ∼ G(λk|α0, β0).
This can similarly be done for matrix tri-factorisation, by placing one ARD over F (using
λFk ) and another over G (using λ
G
l ).
The Gibbs sampling algorithms remain largely the same, simply replacing λF , λG in the
updates by λk. For the multivariate posteriors, we replace λ
FI by diag(λ), a diagonal matrix
where the kth diagonal element is given by λk. The posterior Gibbs sampling distribution
for λk itself can be derived to be another Gamma distribution,
p(λk|D,F ,G, τ) = G(λk|α∗0, β∗0)
where
α∗0 = α0 +
I
2
+
J
2
β∗0 = β0 +
1
2
I∑
i=1
F 2ik +
1
2
J∑
j=1
G2jk
for the real-valued (Gaussian prior) model, and
α∗0 = α0 + I + J β
∗
0 = β0 +
I∑
i=1
Fik +
J∑
j=1
Gjk
for the nonnegative (exponential prior) model. Note that each λk therefore depends only on
the values in the kth column of F and G, and those values in turn depend on the value of
λk: if most values in that column are high, λk gets a small value (indicating that the factor
is active); and if λk has a high value, the kth column will get a Gibbs sampling posterior
around 0, resulting in low values (pushing the other values for this factor down, since it is
inactive).
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Importance value As discussed in the paper, we modify the likelihood with an importances
values αn, αl, αm as follows.
p(θ|R,D,C) ∝
T∏
t=1
p(F t|λt)
N∏
n=1
p(τn)
L∏
l=1
p(τ l)
M∏
m=1
p(τm)
×
N∏
n=1
p(Rn|F tn ,Sn,F un , τn)αn
×
L∏
l=1
p(Dl|F tl ,Gl, τ l)αl
×
M∏
m=1
p(Cm|F tm ,Sm, τm)αm
where θ is the set of model parameters (F t,Sn,Sm,Gl,λt, τn, τ l, τm). We effectively repeat
the dataset Rn αn times, and similarly for Dl,Cm, requiring a better fit to the data. The
Gibbs samplers remain largely the same, with the addition of several α values in the updates.
This is illustrated below for a single datasetD ≈ F ·GT with nonnegative factors, importance
value α, and without ARD.
τ ∼ G(τ |α∗, β∗) α∗ = ατ + α |Ω
|
2
β∗ = βτ + α
1
2
∑
(i,j)∈Ωl
(Dij − F i ·Gj)2
Fik ∼ T N (Fik|µik, τik) µik = 1
τik
−λF + ατ ∑
j∈Ω1i
(Dij −
∑
k′ 6=k
Fik′Gjk′)Gjk

τik = ατ
∑
j∈Ω1i
G2jk
Gjk ∼ T N (Gjk|µjk, τjk) µjk = 1
τjk
−λG + ατ∑
i∈Ω2j
(Dij −
∑
k′ 6=k
Fik′Gjk′)Fik

τjk = ατ
∑
i∈Ω2j
(Fik)
2
Similar derivations can be done for matrix tri-factorisation, and real-valued versions.
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1.3 Hybrid matrix factorisation model
The hybrid matrix factorisation (HMF) model combines all the ideas presented in the pre-
vious two sections. Recall we are given three types of datasets:
1. Main datasets R = {R1, ..,RN}, relating two different entity types. Each dataset Rn ∈
RItn×Iun relates entity types Etn , Eun . We use matrix tri-factorisation to decompose
it into two entity type factor matrices F tn ,F un , and a dataset-specific matrix Sn ∈
RKtn×Kun .
Rn = F tnSn(F un)T +En.
2. Feature datasets D = {D1, ..,DL}, representing features for an entity type. Each
datasetDl ∈ RItl×Jl relates an entity type Etl to Jl features. We use matrix factorisation
to decompose it into one entity type factor matrix F tl , and a dataset-specific matrix
Gl ∈ RJl×Ktl .
Dl = F tl(Gl)T +El.
3. Similarity datasets C = {C1, ..,CM}, giving similarities between entities of the same
entity type. Each dataset Cm ∈ RItm×Itm relates an entity type Etm to itself. We
use matrix tri-factorisation to decompose it into a entity type factor matrix F tm , a
dataset-specific matrix Sm ∈ RKtm×Ktm , and F tm again.
Cm = F tmSm(F tm)T +Em.
Observed entries are given by the sets Ωn = {(i, j)| Rnij observed}, Ωl = {(i, j)| Dlij observed},
Ωm = {(i, j)| Cmij observed}, respectively.
1.3.1 Model definition
The model likelihood functions are
Rnij ∼ N (Rnij|F tni · Sn · F snj , (τn)−1)
Dmij ∼ N (Dlij|F tli ·Glj, (τ l)−1)
Cmij ∼ N (Cmij |F tmi · Sm · F tmj , (τm)−1),
with Bayesian priors
τn, τ l, τm ∼ G(τ ∗|ατ , βτ )
F tik ∼ E(F tik|λtk) or F tik ∼ N (F tik|0, (λtk)−1)
Gljk ∼ E(Gljl|λtlk ) or Gljk ∼ N (Gljl|0, (λtlk )−1)
Snkl ∼ E(Snkl|λnS) or Snkl ∼ N (Snkl|0, (λnS)−1)
Smkl ∼ E(Smkl |λmS ) or Smkl ∼ N (Smkl |0, (λmS )−1).
λtk ∼ G(λtk|α0, β0).
Finally, we add an importance value for each of the Rn,Dl,Cm datasets, respectively
αn, αl, αm.
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1.3.2 Gibbs sampler
The Gibbs sampling algorithm has updates that combine the parameter values given in Ta-
bles 2, 3, and 4, for the single-dataset matrix factorisations, matrix tri-factorisations, and
similarity matrix tri-factorisations. Because there are so many different parts of the models
involved, careful notational definition is essential.
The datasets relating a given entity type Et are indicated by the following sets,
U t1 = {n | Rn ∈ R ∧ tn = t }
U t2 = {n | Rn ∈ R ∧ un = t }
V t =
{
l | Dl ∈D ∧ tl = t
}
W t = {m | Cm ∈ C ∧ tm = t } .
Since the updates for the ARD can be different if a feature dataset is decomposed using
negative factors or real-valued factors for Gl, we also introduce the sets
V t+ =
{
l ∈ V t | Gl is nonnegative} V t− = {l ∈ V t | Gl is real-valued} .
Observed entries per row i and column j are given by
Ωn1i = {j |(i, j) ∈ Ωn} Ωn2j = {i |(i, j) ∈ Ωn}
Ωl1i =
{
j |(i, j) ∈ Ωl} Ωl2j = {i |(i, j) ∈ Ωl}
Ωm1i = {j |(i, j) ∈ Ωm} Ωm2j = {i |(i, j) ∈ Ωm} .
We obtain the following posterior distributions and parameter values:
Noise parameters
τn ∼ G(τn|αn∗ , βn∗ ) αn∗ = ατ + αn
|Ωn|
2
βn∗ = βτ + α
n1
2
∑
(i,j)∈Ωn
(Rnij − F tni · Sn · F unj )2
τ l ∼ G(τ l|αl∗, βl∗) αl∗ = ατ + αl
|Ωl|
2
βl∗ = βτ + α
l 1
2
∑
(i,j)∈Ωl
(Dlij − F tli ·Glj)2
τm ∼ G(τm|αm∗ , βm∗ ) αm∗ = ατ + αm
|Ωm|
2
βm∗ = βτ + α
m1
2
∑
(i,j)∈Ωm
(Cmij − F tmi · Sm · F tmj )2
ARD If F t contains nonnegative factors:
λtk ∼ G(λtk|αtk, βtk) αtk = α0 + It +
∑
l∈V t+
Itl +
∑
l∈V t−
Itl
2
βtk = β0 +
It∑
i=1
Fik +
∑
l∈V t+
Jl∑
j=1
Gjk +
∑
l∈V t−
1
2
Jl∑
j=1
G2jk.
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If F t contains real-valued factors:
λtk ∼ G(λtk|αtk, βtk) αtk = α0 +
It
2
+
∑
l∈V t+
Itl +
∑
l∈V t−
Itl
2
βtk = β0 +
1
2
It∑
i=1
F 2ik +
∑
l∈V t+
Jl∑
j=1
Gjk +
∑
l∈V t−
1
2
Jl∑
j=1
G2jk.
Dataset-specific factor matrices If Gl,Sn,Sm contain nonnegative factors:
Gljk ∼ T N (Gljk|µljk, τ ljk) µljk =
1
τ ljk
−λtlk + τ lαl ∑
i∈Ωl2j
(Dlij −
∑
k′ 6=k
F tlik′G
l
jk′)F
tl
ik

τ ljk = τ
lαl
∑
i∈Ωl2j
(F tlik)
2
Snkl ∼ T N (Snkl|µnkl, τnkl) µnkl =
1
τnkl
−λnS + τnαn ∑
(i,j)∈Ωn
(Rnij −
∑
(k′,l′)6=(k,l)
F tnik′S
n
k′l′F
un
jl′ )F
tn
ik F
un
jl

τnkl = τ
nαn
∑
(i,j)∈Ωn
(F tnik )
2(F unjl )
2
Smkl ∼ T N (Smkl |µmkl, τmkl ) µmkl =
1
τmkl
−λmS + τmαm ∑
(i,j)∈Ωm
(Cmij −
∑
(k′,l′)6=(k,l)
F tmik′ S
m
k′l′F
tm
jl′ )F
tm
ik F
tm
jl

τmkl = τ
mαm
∑
(i,j)∈Ωm
(F tmik )
2(F tmjl )
2
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If Gl,Sn,Sm contain real-valued factors:
Gljk ∼ N (Gljk|µljk, (τ ljk)−1) µljk =
1
τ ljk
τ lαl ∑
i∈Ωl2j
(Dlij −
∑
k′ 6=k
F tlik′G
l
jk′)F
tl
ik

τ ljk = λ
tl
k + τ
lαl
∑
i∈Ωl2j
(F tlik)
2
Glj ∼ N (Glj|µlj,Σlj) µlj = Σlj ·
τ lαl ∑
i∈Ωl2j
DlijF
tl
i

Σlj =
diag(λt) + τ lαl ∑
i∈Ωl2j
F tli ⊗ F tli
−1
Snkl ∼ N (Snkl|µnkl, (τnkl)−1) µnkl =
1
τnkl
τnαn ∑
(i,j)∈Ωn
(Rnij −
∑
(k′,l′)6=(k,l)
F tnik′S
n
k′l′F
un
jl′ )F
tn
ik F
un
jl

τnjk = λ
n
S + τ
nαn
∑
(i,j)∈Ωn
(F tnik )
2(F unjl )
2
Snk ∼ N (Snk |µnk ,Σnk) µnk = Σnk ·
τnαn ∑
(i,j)∈Ωn
(Rnij −
∑
k′ 6=k
F tnik′(S
n
k′ · F unj ))F tnik F unj

Σnk =
λnSI + τnαn ∑
(i,j)∈Ωn
F tnik (F
un
j ⊗ F unj )
−1
Smkl ∼ N (Smkl |µmkl, (τmkl )−1) µmkl =
1
τmkl
τmαm ∑
(i,j)∈Ωm
(Cmij −
∑
(k′,l′) 6=(k,l)
F tmik′ S
m
k′l′F
tm
jl′ )F
tm
ik F
tm
jl

τmkl = λ
m
S + τ
mαm
∑
(i,j)∈Ωm
(F tmik )
2(F tmjl )
2
Smk ∼ N (Smk |µmk ,Σmk ) µmk = Σmk ·
τmαm ∑
(i,j)∈Ωm
(Cmij −
∑
k′ 6=k
F tmik′ (S
m
k′ · F tmj ))F tmik F tmj

Σmk =
λmS I + τmαm ∑
(i,j)∈Ωm
F tmik (F
tm
j ⊗ F tmj )
−1
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Shared factor matrices If F t contains nonnegative factors:
F tik ∼ T N (F tik|µtik, τ tik) µtik =
1
τ tik
−λtk + ∑
n∈Ut1
τnαn
∑
j∈Ωn1i
(Rnij −
∑
k′ 6=k
F tik′(S
n
k′ · F unj ))(Snk · F unj )
+
∑
n∈Ut2
τnαn
∑
i′∈Ωn2i
(Rni′i −
∑
l 6=k
F til(F
tn
i′ · Sn.,l))(F tni′ · Sn.,k)
+
∑
l∈V t
τ lαl
∑
j∈Ωl1i
(Dlij −
∑
k′ 6=k
F tik′G
l
jk′)G
l
jk

+
∑
m∈W t
τmαm
 ∑
j∈Ωm1i
(Cmij −
∑
k′ 6=k
F tik′(S
m
k′ · F tj))(Smk · F tj)
+
∑
i′∈Ωm2i
(Cmi′i −
∑
l 6=k
F til(F
t
i′ · Sm.,l))(F ti′ · Sm.,k)

τ tik =
∑
n∈Ut1
τnαn
∑
j∈Ωn1i
(Snk · F unj )2 +
∑
n∈Ut2
τnαn
∑
i′∈Ωn2i
(F tni′ · Sn.,k)2
+
∑
l∈V t
τ lαl
∑
j∈Ωl1i
(Gljk)
2
+
∑
m∈W t
τmαm
 ∑
j∈Ωm1i
(Smk · F tj)2 +
∑
i′∈Ωm2i
(F ti′ · Sm.,k)2

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If F t contains real-valued factors:
F tik ∼ N (F tik|µtik, (τ tik)−1) µtik =
1
τ tik
∑
n∈Ut1
τnαn
∑
j∈Ωn1i
(Rnij −
∑
k′ 6=k
F tik′(S
n
k′ · F unj ))(Snk · F unj )
+
∑
n∈Ut2
τnαn
∑
i′∈Ωn2i
(Rni′i −
∑
l 6=k
F til(F
tn
i′ · Sn.,l))(F tni′ · Sn.,k)
+
∑
l∈V t
τ lαl
∑
j∈Ωl1i
(Dlij −
∑
k′ 6=k
F tik′G
l
jk′)G
l
jk
+
∑
m∈W t
τmαm
 ∑
j∈Ωm1i
(Cmij −
∑
k′ 6=k
F tik′(S
m
k′ · F tj))(Smk · F tj)
+
∑
i′∈Ωm2i
(Cmi′i −
∑
l 6=k
F til(F
t
i′ · Sm.,l))(F ti′ · Sm.,k)

τ tik =λ
t
k +
∑
n∈Ut1
τnαn
∑
j∈Ωn1i
(Snk · F unj )2 +
∑
n∈Ut2
τnαn
∑
i′∈Ωn2i
(F tni′ · Sn.,k)2
+
∑
l∈V t
τ lαl
∑
j∈Ωl1i
(Gljk)
2
+
∑
m∈W t
τmαm
 ∑
j∈Ωm1i
(Smk · F tj)2 +
∑
i′∈Ωm2i
(F ti′ · Sm.,k)2

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F ti ∼ N (F ti|µti,Σti) µti =Σti ·
∑
n∈Ut1
τnαn
∑
j∈Ωn1i
Rnij(S
n · F unj ) +
∑
n∈Ut2
τnαn
∑
i′∈Ωn2i
Rni′i(F
tn
i′ · Sn)
+
∑
l∈V t
τ lαl
∑
j∈Ωl1i
DlijG
l
j
+
∑
m∈W t
τmαm
 ∑
j∈Ωm1i
Cmij (S
m · F tj) +
∑
i′∈Ωl2i
Cmi′i(F
t
i′ · Sm)

Σti =
diag(λtk) + ∑
n∈Ut1
τnαn
∑
j∈Ωn1i
(Sn · F unj )⊗ (Sn · F unj )
+
∑
n∈Ut2
τnαn
∑
i′∈Ωn2i
(F tni′ · Sn)⊗ (F tni′ · Sn)
+
∑
l∈V t
τ lαl
∑
j∈Ωl1i
(Glj ⊗Glj)
+
∑
m∈W t
τmαm
 ∑
j∈Ωm1i
(Sm · F tj)⊗ (Sm · F tj)
+
∑
i′∈Ωm2i
(F ti′ · Sm)⊗ (F ti′ · Sm)
−1
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2 Model discussion
2.1 Software
We have provided an open-source Python implementation of all models discussed in the
paper, available at https://github.com/ThomasBrouwer/HMF. We furthermore provide all
datasets, preprocessing scripts, and Python code for the experiments. Please refer to the
README in the Github project.
2.2 Complexity
The updates for the Gibbs sampler for Bayesian matrix tri-factorisation have time com-
plexity O(IJK2L), compared to O(IJK2) for Bayesian matrix factorisation. For HMF the
complexity becomes O((N + M + L)I2K3) where I = maxt It and K = maxtKt. Notice
that our model scales linearly in the number of observed datasets. Furthermore,
the random draws for columns of the factor matrices are independent of each other, and
therefore the parameter updates can be formulated as efficient joint matrix operations and
new values drawn in parallel. Alternatively, the draws can be done per row by using a
multivariate posterior, and then all these row-wise draws can be done in parallel as well.
2.3 Missing values and predictions
Missing values can be indicated to the model through the mask sets Ωn,Ωl,Ωm. Note that
this also means that if specific feature values are missing for one of the entities, these features
can still be included for the other entities, simply by marking them as unobserved when we
do not know their value. This is much better than imputing those values, for example using
the row or column average, as the model will still fit to those imputed values.
The missing values can then be predicted, by using the posterior draws of the Gibbs sampler
(after burn-in and thinning) to estimate the posteriors of the factor matrices. For example, if
we wish to predict missing values in the matrix Dl, we estimate F tl and Gl, and predictions
for the missing entries are given by F tl · (Gl)T .
2.4 Initialisation
Gibbs sampling can easily get stuck in a local minimum of posterior likelihood, and therefore
initialisation of the random variables is essential to obtain a good solution. There are two
obvious ways to do this. Since the user specifies the values of the hyperparameters, α0, β0,
ατ , βτ , λ
n
S, λ
m
S , we can use the model definition to initialise the variables F
t, Gl, Sn, Sm,
τn, τ l, τm, λtk either using the expectation of the prior model distribution, or by randomly
drawing their value according to that distribution.
Alternatively, we can initialise the entity type factor matrices F t using K-means clustering,
as suggested by Ding et al. [2006], and initialise the dataset-specific matrices Sn,Sm,F l
using least squares. This can be done using the Moore-Penrose pseudo-inverse (+), as long
as the dataset-specific matrices (Sn,Sm,Gl) are real-valued. For example,
Sn = (F tn)+ ·Rn · ((F un)T )+.
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If the datasets are not real-valued, we can still initialise Sn or the other factor matrices in this
way, but then set all values below zero to zero. We measure the effectiveness of the different
initialisation methods in Section 4.3, which shows that this combination of K-means and
least squares initialisation generally gives the fastest convergence.
2.5 Relation to tensor decomposition
Multiple matrix factorisation and tri-factorisation methods are closely linked with tensor
decomposition. Here, we explore some of these connections. In particular, we show that the
CANDECOMP/PARAFAC (CP, Harshman [1970]) method is a less general version of the
multiple matrix tri-factorisation (MMTF) part of our HMF model; and furthermore that the
Tucker Decomposition (TD, Tucker [1966]), without its orthogonality constraints, is equiv-
alent to MMTF. All three decompositions are illustrated in Figure 1, and we define them
mathematically below.
The CP method decomposes a given tensor R ∈ RI×J×N into the sum of K rank-1 tensors.
This is effectively a generalisation of matrix factorisation to three (rather than two) dimen-
sions, with each dimension getting its own factor matrix: F 1 ∈ RI×K ,F 2 ∈ RJ×K ,S ∈
RN×K . Overall, we perform the factorisation R = F 1⊗F 2⊗S, where ⊗ denotes the matrix
outer product. Each individual entry in R is decomposed as follows:
Rijn =
K∑
k=1
F 1ik · F 2jk · Snk. (1)
The Tucker decomposition is defined similarly, but in addition to the three factor matrices,
we also get a core tensorG ∈ RK×L×Q, and the factor matrices have its own number of latent
factors K,L,Q; F 1 ∈ RI×K ,S ∈ RJ×L,F 2 ∈ RN×Q. We now factorise R = G • 1F 1 • 2F 2 • 3S,
where •i denotes the matrix dot product using the ith dimension of tensor G. Individual
entries in R are decomposed as:
Rijn =
K∑
k=1
L∑
l=1
Q∑
q=1
F 1ik · F 2jl · Snq ·Gklq. (2)
Now consider the multiple matrix tri-factorisation part of our HMF model. Say we are given
N datasets Rn, all spanning the same two entity types E1, E2, with I rows, J columns, K
row factors (for entity type E1), and L row factors (for entity type E2). Performing MMTF
on these datasets can be seen as concatenating the N matrices into one big tensor. Each
MMTF
≈
TD
≈
CP
≈
⊗
Figure 1: Overview of the CANDECOMP/PARAFAC (CP, left), Tucker Decomposition (TD, middle), and
multiple matrix tri-factorisation (MMTF, right) methods. CP uses the outer product (⊗), whereas TD and
MMTF use the matrix product.
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entry is decomposed as:
Rnij =
K∑
k=1
L∑
l=1
F 1ik · F 2jl · Snkl. (3)
Firstly, compare this with the TD formulation. If we define a new matrix Hnkl =
∑Q
q=1 Snq ·
Gklq = Sn ·Gkl, we can rewrite the TD expression as:
Rijn =
K∑
k=1
L∑
l=1
F 1ik · F 2jl ·Hnkl. (4)
Note that this is now equivalent to our MMTF expression in Equation 3, with F 1ik ↔
F 1ik, F
2
jl ↔ F 2jl, Snkl ↔ Hnkl. Since both the S and G matrices have to be inferred by our
model, we can in fact merge them into one – as long as no further constraints are placed
on them individually. Often in the TD method the three factor matrices (F 1,F 2,S) have
orthogonality constraints placed on them. If these constraints are dropped, TD is equivalent
to MMTF.
Moving on to CP, consider constraining our MMTF model to have only diagonal entries in
the Sn matrices (so that Snkl = 0 for k 6= l). Equation 3 then becomes:
Rnij =
K∑
k=1
F 1ik · F 2jk · Snkk. (5)
This is equivalent to the CP formulation in Equation 1, with F 1ik ↔ F 1ik, F 2jk ↔ F 2jk, Snkk ↔
Snk, showing that CP is a constrained version of MMTF, where the middle factor matrices
Snkl are constrained to be diagonal.
Finally, we wanted to validate that the more general formulation offered by our HMF model
is necessary to obtain good predictive performances, by comparing it with the CP method.
We constrained our HMF model to have diagonal Sn matrices (we call this method HMF
CP), but otherwise the exact same Bayesian priors and settings. The results are given in
Tables 5 and 6. We can see that in the in-matrix prediction setting CP still does fairly
well, although our unconstrained MMTF model (HMF D-MTF) outperforms it on all four
datasets. However, in the out-of-matrix prediction setting CP does not manage to give
sensible predictions, barely doing better than the gene average baseline.
Table 5: Mean squared error (MSE) of 10-fold in-matrix cross-validation results on the drug sensitivity
datasets. The best performances are highlighted in bold.
Method GDSC IC50 CTRP EC50 CCLE IC50 CCLE EC50
HMF D-MF 0.0775 0.0919 0.0592 0.1062
HMF D-MTF 0.0768 0.0908 0.0558 0.1073
HMF CP 0.0796 0.0913 0.0560 0.1104
19
Table 6: Mean squared error (MSE) of 10-fold out-of-matrix cross-validation results on the methylation
datasets. The best performances are highlighted in bold.
Method GM, PM to GE GE, GM to PM GE, PM to GM
Gene average 1.009 1.008 1.009
HMF D-MF 0.788 0.735 0.602
HMF D-MTF 0.850 0.798 0.640
HMF S-MF 0.820 0.794 0.672
HMF CP 1.006 0.972 0.968
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3 Datasets and preprocessing
3.1 Drug sensitivity datasets
We will now describe the preprocessing steps undertaken for the drug sensitivity datasets
used in the paper. We used four different datasets:
• Genomics of Drug Sensitivity in Cancer (GDSC v5.0, Yang et al. [2013]) – giving the
natural log of IC50 values for 139 drugs across 707 cell lines, with 80% observed entries.
• Cancer Therapeutics Response Portal (CTRP v2, Seashore-Ludlow et al. [2015]) – giving
EC50 values for 545 drugs across 887 cell lines, with 80% observed entries.
• Cancer Cell Line Encyclopedia (CCLE, Barretina et al. [2012]) – giving both IC50 and
EC50 values for 24 drugs across 504 cell lines, with 96% and 63% observed entries
respectively.
IC50 values indicate the required drug concentration needed to reduce the activity of a given
cell line (cancer type in a tissue) by half. We thus measure when an undesired effect has
been inhibited by half. With EC50 values we measure the maximal (desired) effect a drug
can have on a cell line, and then measure the concentration of the drug where we achieve
half of this value. In both cases, a lower value is better.
In this paper we are most interested in enhancing predictive power by integrating differ-
ent datasets. Therefore we focus on drugs and cell lines for which at least two of the four
datasets have values available, giving 52 drugs and 630 cell lines. Venn diagrams displaying
the overlaps between drugs and cell lines are given in Figures 2a and 2b, respectively. The
CTRP dataset contains a large number of small molecule probes (311) causing very little
intersection with the other datasets. We also filtered out cell lines with no features available,
as discussed in Subsection 3.3.
8 4994
91
6
36
6
CCLE
CTRP
GDSC
Intersections drugs for drug sensitivity datasets
(a) Drugs
39
279
184
261
22
165
259
CCLE
CTRP
GDSC
Intersections cell lines for drug sensitivity datasets
(b) Cell lines
Figure 2: Venn diagrams of the drugs and cell lines in the four datasets.
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(a) GDSC IC50 (b) CTRP EC50 (c) CCLE IC50 (d) CCLE EC50
Figure 3: Plots of the distribution of values in the drug sensitivity datasets, after capping the extremely
high values in the CTRP EC50 and GDSC IC50 datasets to 20.
3.2 Preprocessing drug sensitivity values
The CCLE and CTRP datasets all give the drug concentration levels, but the GDSC dataset
gives the natural log transform of these values. We undo this transform by taking the ex-
ponent of each value. The drug sensitivity values for the CCLE IC50 and EC50 datasets lie
in the range [0,8] and [0,10], but the other two datasets sporadically have extremely large
values. This is a result of the curve fitting procedure used to approximate IC50 and EC50,
and in those cases it indicates an inefficient drug for the cell line. We cap all values above
20 to 20 to resolve this issue, and as a result obtain a similar shape of distribution of values
to the CCLE datasets. Finally, we map the values in each row (per cell line) to the range
[0,1]. This is shown in Figure 3, where we see that the data tends to be bimodal.
3.3 Features
We also want to incorporate feature information, which is readily provided by the GDSC
dataset for 399 of the 630 cell lines. This gave us gene expression information (13321 genes,
positive values), copy number variations (CNV; 426 features, count data), and mutations
(82, binary data). We filtered out cell lines without this information.
For the drugs we used the PubChem Identifier Exchange Service (https://pubchem.ncbi.
nlm.nih.gov/idexchange/idexchange.cgi) to obtain the PubChem identifiers for all the
drugs. Where there were multiple, we used the one in the GDSC database, or otherwise the
first one. We then used the PaDeL-Descriptor software (http://www.yapcwsoft.com/dd/
padeldescriptor/) to extract 1D and 2D descriptors, as well as Pubchem fingerprints of
functional groups in the drugs. The GDSC dataset has drug target information available
for 48 out of the 52 drugs, which we extracted from their website and encoded as a binary
dataset. For the four remaining targets we mark the entries as unknown using the mask
matrix in the feature dataset and kernel. We removed features with the same value across
all drugs.
For each of the feature datasets we constructed a similarity kernel. For binary data we used
a Jaccard kernel, and for real-valued data we first standardised each feature to have zero
mean and unit variance, and then used a Gaussian kernel to compute similarities, with as
variance parameter the number of features. The resulting distributions of kernel similarity
values are given in Figure 4. We found that adding the similarity kernels in our HMF model
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(a) Gene expression (b) CNV (c) Mutations
(d) 1D 2D descriptors (e) Fingerprints (f) Targets
Figure 4: Plots of the distribution of similarity values in the kernel matrices based on the feature
datasets. The similarity scores based on drug fingerprints, drug targets, and cell line mutations were
constructed using a Jaccard kernel. The scores for gene expression data, copy number variations, and
1D and 2D descriptors were computed using a Gaussian kernel after standardising the values per feature
(zero mean, unit variance) and using the number of features as the variance parameter.
did not improve the predictions. This is because adding dissimilar datasets makes it very
hard (if not impossible) to find a good solution, and instead converges to a bad one.
The datasets are summarised in Table 7, and represented graphically in Figure 5. Of the
remaining datasets (52 drugs by 399 cell lines), 95.1% of the entries have a value in at
least one of the four datasets, and 62.9% have an entry in two or more. GDSC IC50 has
67.9% observed entries, CTRP EC50 has 72.3%, CCLE IC50 has 18.8%, and CCLE EC50
has 11.4%. This is also shown in Figure 5. Individually, the GDSC dataset contains entries
for 48 drugs and 399 cell lines (73.6% observed), CTRP spans 46 drugs and 379 cell lines
(86.0% observed), and finally CCLE IC50 and EC50 have 16 drugs and 253 cell lines (96.4%
and 58.6% observed).
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Drugs Cell lines
Drug features Cell line features
GDSC
CTRP
CCLE IC50
CCLE EC50
Drug kernels Cell line kernels
Figure 5: The datasets used for drug sensitivity prediction on the left; and the overlap of values between the
four datasets on the right.
Table 7: Drug sensitivity datasets and feature datasets, summarising the entities they relate, the sizes of the
datasets, and the fraction of observed entries.
Dataset Entities Size Observed
GDSC IC50 Cell lines, drugs 399, 52 67.9%
CTRP EC50 Cell lines, drugs 399, 52 72.3%
CCLE IC50 Cell lines, drugs 399, 52 18.8%
CCLE EC50 Cell lines, drugs 399, 52 11.4%
Targets Drugs, targets 52, 53 92.3%
1D2D Drugs, 1D 2D descriptors 52, 1160 100%
FP Drugs, fingerprints 52, 495 100%
Targets kernel Drugs, drugs 52, 52 85.2%
1D2D kernel Drugs, drugs 52, 52 100%
FP kernel Drugs, drugs 52, 52 100%
CNV Cell lines, CNVs 399, 426 100%
Mutations Cell lines, mutations 52, 82 100%
Gene expression kernel Cell lines, cell lines 399, 399 100%
CNV kernel Cell lines, cell lines 399, 399 100%
Mutations kernel Cell lines, cell lines 399, 399 100%
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3.4 Methylation and gene expression datasets
The preprocessing for the methylation and gene expression datasets is much simpler. We
obtained three datasets from the The Cancer Genome Atlas (TCGA, Koboldt et al. [2012]):
promoter-region methylation (PM), gene body methylation (GM), and gene expression (GE)
profiles for 254 breast cancer patients. This dataset originally spanned 13966 genes, but we
focused on 160 breast cancer driver genes, given by the IntOGen database (Gonzalez-Perez
et al. [2013]). We standardised each of the datasets to have zero mean and unit standard
deviation per gene. Plots of the datasets containing the 160 genes, before and after standar-
dising, can be found in Figure 6.
To construct the similarity kernels for the HMF S-MF model, giving the similarity of samples,
we used a Gaussian kernel with σ2 = no. genes. The kernel value distributions are plotted
in Figure 7. Notice the Gaussian-like distribution of values between [0,1]. If we generate
values randomly from our HMF model’s probabilistic definition (for example using value 1
for all hyperparameters, and then randomly sampling values from the prior distributions),
we obtain a similar distribution of values. σ2 was chosen in such a way to match the model
definition more closely.
(a) Gene expression,
unstandardised
(b) Promoter-region methylation,
unstandardised
(c) Gene body methylation,
unstandardised
(d) Gene expression,
standardised
(e) Promoter-region methylation,
standardised
(f) Gene body methylation,
standardised
Figure 6: Plots of the distribution of the methylation datasets, before standardising (top row) and after
(bottom row).
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(a) Gene expression kernel (b) Promoter-region methylation kernel (c) Gene body methylation kernel
Figure 7: Plots of the distribution of the methylation kernels.
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4 Additional experiments
We performed several additional experiments on the drug sensitivity and methylation datasets,
to explore the advantages and limits of our models. In particular, we looked at: the run-time
performance of the models; the effectiveness of automatic model selection using the Auto-
matic Relevance Determination (ARD) Bayesian prior; the best initialisation approach; the
best values to use for the dataset importances α; and the trade-offs of our hybrid choices:
effects of factorisation types and nonnegativity constraints on predictive performance.
4.1 Run-time comparison
In this section we give a rough indication of the run-time performances of the models we
compared in our experiments. We compare the time it takes for most of the matrix factori-
sation methods (HMF D-MF, HMF D-MTF, BNMF, BNMTF, NMF, NMTF, and Multiple
NMF) on the four drug sensitivity datasets. In particular, we give the number of iterations
we used in our experiments for each model, the total run-time it took to train each model,
and the time per iteration of the model updates. We use Kt = 10, K = 10, L = 10 for all
models.
The run-time performances on the drug sensitivity datasets are given in Table 8. Often
the matrix factorisation variants are faster than the matrix tri-factorisation versions (up to
six times, in the case of NMF and NMTF). The non-probabilistic methods give the fastest
run-time (both per iteration, and total), but our experiments show that their predictive
performance is worse and they are more prone to overfitting. Our HMF models incur a
slightly higher run-time than the other Bayesian models (BNMF, BNMTF), due to having
to consider all four datasets at the same time, but only by a factor of roughly two (despite
there being four datasets in total).
Note that when we use cross-validation to measure the predictive performances, our HMF
models do not need to run nested cross-validation to choose the dimensionality (Kt), whereas
the other matrix factorisation models (BNMF, BNMTF, NMF, NMTF, Multiple NMF) do.
This actually makes our models faster in cross-validation.
Table 8: Run-time performances of the matrix factorisation models on each of the four drug sensitivity
datasets, giving the total number of iterations (It) used to train each model in our experiments (the same
on each dataset), and then for each dataset the average number of seconds per iteration (s / it), and the
total time in seconds to train a single model (Total).
GDSC IC50 CTRP EC50 CCLE IC50 CCLE EC50
Model Iterations s / it Total s / it Total s / it Total s / it Total
HMF D-MF 200 0.120 23.9 0.119 23.8 0.058 11.6 0.052 10.5
HMF D-MTF 200 0.303 60.6 0.293 58.6 0.148 29.5 0.148 29.6
BNMF 1000 0.061 61.2 0.059 58.8 0.034 34.3 0.037 37.0
BNMTF 500 0.112 56.1 0.107 53.5 0.052 26.1 0.056 28.1
NMF 1000 0.007 6.9 0.007 6.6 0.002 2.3 0.002 2.0
NMTF 1000 0.037 36.6 0.033 33.4 0.009 9.3 0.010 9.8
Multiple NMF 1000 0.017 16.9 0.017 17.0 0.012 11.6 0.011 11.0
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All run-time experiments were conducted on a MacBook Pro laptop, with 2.2 GHz Intel
Core i7 processor, 16 GB 1600 MHz DDR3 memory, and an Intel Iris Pro 1536 MB Graphics
card.
4.2 Model selection
Our model employs the ARD prior to perform automatic model selection. In this experi-
ment, we verify how effective this is. We repeat the in-matrix cross-validation experiments
on the four drug sensitivity experiments, for the HMF D-MF (multiple matrix factorisation)
and HMF D-MTF (multiple matrix tri-factorisation) models. We vary the values for Kt,
using the values [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 25, 30].
Usually when we add more factors to a matrix factorisation models, it gives the model more
freedom to fit well to the data, eventually leading to overfitting. Hence, the average cross-
validation performance should initially go down, and then go up again as it starts overfitting.
If the ARD works as desired, and we add more factors (Kt increases), the ARD will turn
them off and use a similar number of factors to before. This should result in less overfitting
than the equivalent model with no ARD, resulting in a flatter curve going back up as the
number of factors increase.
We compare the effects of adding ARD to the HMF model in Figure 8. Here, we clearly see
that adding ARD to the model consistently reduces overfitting on all four drug sensitivity
datasets. ARD is not perfect, and we can still see that the curve goes up as the values for
Kt increase, but this overfitting is significantly less severe than the models without ARD.
Usage recommendations Always use ARD to reduce overfitting in the model. Even though
ARD does not always entirely eliminate the need for model selection (there is still some
overfitting as Kt becomes very large), it generally makes it much less critical to try a large
range of dimensionalities to find the best one. Instead, trying one or a couple will prove just
as effective.
4.3 Initialisation
The initialisation method can have a huge impact on performance. Initialise too well, and
it leads to overfitting very quickly. Initialise poorly, and your model may not converge to a
good solution.
As discussed in Section 2.4, there are several ways to initialise the Gibbs sampling parameter
values. Here, we measure the convergence of the HMF D-MF and HMF D-MTF models
(nonnegative shared factors, real-valued private factors) on the drug sensitivity datasets.
We try the following initialisation approaches:
1. Exp: All parameters initialised using expectation.
2. Random: ARD initialised using expectation, all other parameters using random draws.
28
(a) GDSC IC50 (b) CTRP EC50
(c) CCLE IC50 (d) CCLE EC50
Figure 8: Graphs showing the cross-validation performance of in-matrix predictions on the drug sensitivity
datasets, where we vary the dimensionality Kt for our HMF models (HMF D-MF in red, HMF D-MTF
in blue), both for HMF with ARD (o), and without (x). Adding ARD clearly reduces overfitting as Kt
increases.
3. K-means, exp: Entity type factor matrices F t initialised using K-means, all other
parameters using expectation.
4. K-means, random: Entity type factor matrices F t initialised using K-means, ARD
initialised using expectation, and all other factor matrices using random draws.
5. Exp, least squares: Entity type factor matrices F t and ARD initialised using expec-
tation, and all other factor matrices using least squares.
6. Random, least squares: Entity type factor matrices F t initialised using random
draws, ARD initialised using expectation, and all other factor matrices using least
squares.
7. K-means, least squares: Entity type factor matrices F t initialised using K-means,
ARD initialised using expectation, and all other factor matrices using least squares.
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(a) HMF D-MF, GDSC IC50 (b) HMF D-MF, CTRP EC50
(c) HMF D-MF, CCLE IC50 (d) HMF D-MF, CCLE EC50
(e) HMF D-MTF, GDSC IC50 (f) HMF D-MTF, CTRP EC50
(g) HMF D-MTF, CCLE IC50 (h) HMF D-MTF, CCLE EC50
Figure 9: Graphs showing the convergence of the HMF D-MF (top two rows) and HMF D-MTF (bottom
two rows) models on the four drug sensitivity datasets, for the seven different initialisation approaches.
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The plots of convergence for HMF D-MF and HMF D-MTF are given in Figure 9. We can see
that the K-means with least squares initialisation strategy (dark blue) provides the fastest
convergence on half of the datasets, oftentimes significantly faster. Random for F t and least
squares also performs well. The other strategies sometimes provide faster convergence, but
none of them do so consistently.
Recommendation The fastest convergence is generally provided by combining K-means
initialisation for F t with least squares for the other factor matrices. Random initialisation
for F t with least squares also works well.
4.4 Importance value
We experimented with different values for the importance values α, for the out-of-matrix
prediction setting. Specifically, we consider the case where we predict one dataset (either
gene expression, promoter-region methylation, or gene body methylation) using the other
two datasets as additional datasets.
We vary the value of α for the dataset we are trying to predict (α0) as well as for the two
other datasets we are learning from (α1, α2), using the values [0.25, 0.5, 1.0, 1.5, 2.0]. We use
Kt = 10 for all experiments, non-negative factors for the shared factor matrices, and real-
valued for the private ones. For initialisation we use K-means for the shared factor matrices,
and least squares for the private (real-valued) ones.
We perform 10-fold cross-validation, taking out 10% of the samples each time for the dataset
we are trying to predict, and then measuring the mean squared error (MSE) of predictions.
The average performances can be found in Table 9, for both HMF D-MF (multiple matrix
factorisation) and HMF D-MTF (multiple matrix tri-factorisation).
For the HMF D-MF model (left column) we see that datasets with low predictivity (such
as GE and PM – note the high MSE) have the best parameter values when the importance
of the dataset to be predicted (α0) is low, and the importance of the datasets to learn from
(α1, α2) is high. This is presumably because higher importance values lead to a better fit to
the data, and if there is low predictivity, we should not fit to the data too much (otherwise
we might overfit). In contrast, when the predictivity is high (such as GM), the importance
value for all datasets should not be too low, because this results in a poor fit to the data
and hence poor predictions.
For the HMF D-MTF model (right column) we see a similar effect, in that if the predictivity
is better, the best values for the importance increase. However, for this approach all of the
importance values should generally be set low if the datasets are different.
We conducted the same experiment for the approach based on similarity kernels, where we
use the same ones as used in the out-of-matrix predictions from the paper. For the dataset
we are trying to predict we decompose it using matrix factorisation (HMF S-MF). Matrix
tri-factorisation could have also been chosen, but because the third dataset is not shared in
this case, it is equivalent to matrix factorisation (in fact, we get very similar tables as the
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ones shown for HMF S-MF). As before, we use nonnegative factors for the shared matrices,
real-valued factors for the private ones, and K-means and least squares for initialisation.
The results can be found in Table 10. Here, we see that the importance value is much less
important, as long as it is not lower than 1.0.
Recommendation If the datasets are very dissimilar and have low predictivity, use a low
importance value for the main dataset for which we are trying to predict values (like 0.5).
When using HMF D-MF, use a higher importance value for the other datasets (like 1.5),
but when using HMF D-MTF, use a low importance value as well (like 0.5). If the datasets
are more similar, use normal importance values (1.0) for all datasets. Finally, when using
similarity kernels (HMF S-MF), use the normal importance value for the kernels (1.0).
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Table 9: Performances of out-of-matrix cross-validation results for HMF D-MF (left column) and D-MTF
(right column), where we vary the importance value for the dataset we are trying to predict (α0), and for
the other two datasets we are learning from (α1, α2). We have three different datasets (gene expression,
GE; gene body methylation, GM; and promoter region methylation, PM). We therefore have three different
prediction settings. We have highlighted the most promising parameter value areas in green, and the least
promising in red.
HMF D-MF, GM + PM → GE
GM (α1), PM (α2)
GE (α0) 0.25 0.5 1.0 1.5 2.0
0.25 0.878 0.843 0.835 0.831 0.832
0.5 0.845 0.849 0.829 0.832 0.829
1.0 0.848 0.916 1.195 1.322 0.831
1.5 0.871 0.948 1.288 1.407 1.470
2.0 0.896 0.966 1.392 1.711 1.782
HMF D-MTF, GM + PM → GE
GM (α1), PM (α2)
GE (α0) 0.25 0.5 1.0 1.5 2.0
0.25 0.866 0.906 0.941 0.950 0.954
0.5 0.874 0.870 0.914 0.941 0.945
1.0 0.933 0.985 0.940 0.942 0.961
1.5 0.959 0.958 1.065 1.026 1.000
2.0 0.957 1.080 1.211 1.145 1.147
HMF D-MF, GE + GM → PM
GE (α1), GM (α2)
PM (α0) 0.25 0.5 1.0 1.5 2.0
0.25 0.859 0.799 0.795 0.799 0.798
0.5 0.811 0.812 0.783 0.783 0.784
1.0 0.789 0.814 0.987 0.788 0.783
1.5 0.784 0.809 1.070 1.247 0.870
2.0 0.798 0.835 1.111 1.280 1.255
HMF D-MTF, GE + GM → PM
GE (α1), GM (α2)
PM (α0) 0.25 0.5 1.0 1.5 2.0
0.25 0.862 0.893 0.943 0.946 0.947
0.5 0.841 0.885 0.898 0.943 0.944
1.0 0.852 0.848 1.012 0.885 0.904
1.5 0.876 0.866 0.900 1.080 0.904
2.0 0.884 0.881 0.900 1.096 1.099
HMF D-MF, GE + PM → GM
GE (α1), PM (α2)
GM (α0) 0.25 0.5 1.0 1.5 2.0
0.25 0.790 0.708 0.703 0.697 0.701
0.5 0.724 0.670 0.687 0.688 0.685
1.0 0.698 0.657 0.659 0.670 0.685
1.5 0.698 0.655 0.667 0.657 0.666
2.0 0.689 0.668 0.671 0.676 0.665
HMF D-MTF, GE + PM → GM
GE (α1), PM (α2)
GM (α0) 0.25 0.5 1.0 1.5 2.0
0.25 0.773 0.775 0.851 0.854 0.861
0.5 0.761 0.746 0.774 0.818 0.850
1.0 0.782 0.757 0.754 0.786 0.779
1.5 0.832 0.752 0.745 0.783 0.795
2.0 0.836 0.811 0.802 0.791 0.805
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Table 10: Performances of out-of-matrix cross-validation results for HMF S-MF, where we vary the impor-
tance value for the dataset we are trying to predict (α0), and for the other two datasets we are learning from
(α1, α2). We have three different datasets (gene expression, GE; gene body methylation, GM; and promoter
region methylation, PM). We therefore have three different prediction settings. We have highlighted the
most promising parameter value areas in green, and the least promising in red.
HMF S-MF, GM + PM → GE
GM (α1), PM (α2)
GE (α0) 0.25 0.5 1.0 1.5 2.0
0.25 0.873 0.870 0.871 0.880 0.879
0.5 0.852 0.850 0.853 0.852 0.849
1.0 0.839 0.835 0.846 0.843 0.842
1.5 0.872 0.839 0.837 0.842 0.840
2.0 0.945 0.849 0.834 0.845 0.833
HMF S-MF, GE + GM → PM
GM (α1), PM (α2)
GE (α0) 0.25 0.5 1.0 1.5 2.0
0.25 0.858 0.858 0.866 0.859 0.854
0.5 0.829 0.830 0.823 0.832 0.828
1.0 0.824 0.813 0.815 0.814 0.814
1.5 0.853 0.804 0.806 0.812 0.808
2.0 0.898 0.858 0.810 0.807 0.809
HMF S-MF, GE + PM → GM
GM (α1), PM (α2)
GE (α0) 0.25 0.5 1.0 1.5 2.0
0.25 0.762 0.771 0.782 0.796 0.797
0.5 0.722 0.724 0.740 0.742 0.753
1.0 0.701 0.706 0.707 0.718 0.721
1.5 0.756 0.703 0.702 0.709 0.710
2.0 0.757 0.710 0.702 0.697 0.701
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4.5 Negativity constraints
Negativity constraints have two advantages. Firstly, they make it easier to analyse the factor
values after performing matrix factorisation, and for example identify clusters in the data.
With real-valued factors this can be a lot more complicated. Secondly, the nonnegativity
constraints can reduce overfitting on sparse or noisy datasets.
We measured the effects of nonnegativity constraints on our HMF models. On the drug
sensitivity datasets we tried three variants: nonnegative (all factor matrices are nonnega-
tive), real-valued (all factor matrices are real-valued), and semi-nonnegative (shared factor
matrices are nonnegative, dataset-specific ones are real-valued). On the gene expression and
methylation datasets we tried the real-valued and semi-nonnegative versions. For the vari-
ants containing real-valued factor matrices, we also see whether there is a difference between
row-wise and column-wise posterior draws.
We ran 10-fold cross-validation for in-matrix predictions of the drug sensitivity datasets. We
use Kt = 10, K-means initialisation for the F
t matrices, and least squares initialisation for
the other matrices. Results are given in Table 11, where we see that the entirely real-valued
models consistently outperform all other versions, for both HMF D-MF and D-MTF. In
addition, row-wise draws perform better than column-wise ones.
Similarly, we ran 10-fold cross-validation for out-of-matrix predictions of the drug sensitiv-
ity datasets. We ran the HMF D-MF, HMF D-MTF, and HMF S-MF models, again with
Kt = 10, and K-means and least squares initialisation. For HMF D-MF we used importance
value 0.5 for all three datasets. For HMF D-MTF, 1.5 for the main dataset we are trying to
predict, and 0.5 for the others. For HMF S-MF we used 1.0 for all datasets. These results
are given in Table 12, showing again that the real-valued version performs better for HMF
D-MF, D-MTF, and S-MF. Column draws sometime do best, but generally row-wise draws
are the best options.
Although nonnegativity can reduce the chance for overfitting, it comes at the cost of worse fit-
ting to the data, as the nonnegativity makes convergence harder. This probably explains the
lower predictive performance in this experiment for the nonnegative and semi-nonnegative
models. The Bayesian nature of the models already reduces overfitting, potentially making
the nonnegativity redundant. However, if the data is very sparse, and hence overfitting is
more likely, the nonnegativity could be a great option.
To explore the advantages of nonnegativity in sparse settings, we repeat the experiments for
sparse data predictions that were performed in the main paper on the CTRP drug sensitivity
dataset, comparing the five different versions of HMF D-MF and D-MTF from the previous
section. We vary the fraction of observed data, splitting the data randomly into train and
test 10 times, and taking the average performance of predictions. This is shown for both
methods in Figure 10. We do see that when the sparsity increases to very high levels like
90%, the nonnegative model (in dark blue) outperforms the real-valued model with row
draws (in light blue). This is especially true for the HMF D-MTF model.
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Table 11: Performances of in-matrix cross-validation results for HMF D-MF (top table) and D-MTF (bottom
table) on the drug sensitivity datasets, where we vary the nonnegativity of the matrices. We try nonnegative,
semi-nonnegative, and real-valued variants, and for the real-varied variants try both row-wise draws and
column-wise draws. The best performances are highlighted in bold.
HMF D-MF MSE
F t Gl GDSC IC50 CTRP EC50 CCLE IC50 CCLE EC50
Nonnegative Nonnegative 0.0783 0.0907 0.0544 0.1083
Nonnegative Real-valued (row) 0.0764 0.0899 0.0541 0.1069
Nonnegative Real-valued (column) 0.0760 0.0903 0.0572 0.1050
Real-valued (row) Real-valued (row) 0.0758 0.0878 0.0519 0.1028
Real-valued (column) Real-valued (column) 0.0761 0.0889 0.0521 0.1029
HMF D-MTF MSE
F t Sn GDSC IC50 CTRP EC50 CCLE IC50 CCLE EC50
Nonnegative Nonnegative 0.0802 0.0916 0.0573 0.1133
Nonnegative Real-valued (row) 0.0773 0.0899 0.0558 0.1110
Nonnegative Real-valued (column) 0.0780 0.0904 0.0549 0.1116
Real-valued (row) Real-valued (row) 0.0770 0.0883 0.0535 0.1011
Real-valued (column) Real-valued (column) 0.0799 0.0904 0.0572 0.1101
Table 12: Performances of out-of-matrix cross-validation results for HMF D-MF (top table), D-MTF (middle
table), and S-MF (bottom table), on the gene expression and methylation datasets, where we vary the
nonnegativity of the matrices. We try semi-nonnegative and real-valued variants, and also row-wise draws
and column-wise draws. The best performances are highlighted in bold.
HMF D-MF MSE
F t Gl GM, PM to GE GE, GM to PM GE, PM to GM
Nonnegative Real-valued (row) 0.880 0.792 0.670
Nonnegative Real-valued (column) 0.851 0.803 0.672
Real-valued (row) Real-valued (row) 0.834 0.775 0.651
Real-valued (column) Real-valued (column) 0.839 0.769 0.647
HMF D-MTF MSE
F t Sn GM, PM to GE GE, GM to PM GE, PM to GM
Nonnegative Real-valued (row) 0.959 0.864 0.755
Nonnegative Real-valued (column) 0.985 0.869 0.777
Real-valued (row) Real-valued (row) 0.893 0.822 0.756
Real-valued (column) Real-valued (column) 0.909 0.837 0.738
HMF S-MF MSE
F t Sn GM, PM to GE GE, GM to PM GE, PM to GM
Nonnegative Real-valued (row) 0.846 0.818 0.713
Nonnegative Real-valued (column) 0.836 0.811 0.723
Real-valued (row) Real-valued (row) 0.815 0.805 0.697
Real-valued (column) Real-valued (column) 0.849 0.823 0.721
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(a) HMF D-MF (b) HMF D-MTF
Figure 10: Graphs showing the performance for the different negativity options for the HMF D-MF (left)
and HMF D-MTF (right) models, as the sparsity of the CTRP dataset increases. We plot the average
mean squared error (MSE) across 10 random training and data splits.
Recommendation It is generally best use Gaussian priors for all factor matrices, resulting
in entirely real-valued models. Row-wise draws most often give better performances than
column-wise draws. In the case of very sparse matrices, nonnegative models can reduce
overfitting.
4.6 Factorisation types
Finally, we experiment with the choice of factorisationt types. Recall that each dataset can
be factorised either using matrix factorisation (Dl) or matrix tri-factorisation (Rn). For the
drug sensitivity dataset, there are therefore a number of hybrid factorisation possibilities:
using matrix factorisation for all (as used in the main paper; HMF D-MF), using matrix
tri-factorisation for all (HMF D-MTF), using matrix factorisation on one dataset and tri-
factorisation for the other three, or using matrix factorisation on two datasets and tri-
factorisation on two as well. Note that applying matrix tri-factorisation on only one dataset
is equivalent to using matrix factorisation on all four (since the second factor matrix is not
shared with any other dataset). In this section we explore some of these choices.
Methylation data
We firstly consider the methylation datasets (GE, GM, and PM). We computed the Spear-
man correlation of values in each pair of these datasets, as given in Table 13. Here we see
that GM and PM are (weakly) positively correlated, and GE and PM are (weakly nega-
tively) correlated. We then performed 10-fold out-of-matrix cross-validation experiments (as
before), varying the factorisation types on the three datasets. For simplicity we used Kt = 10
and α = 0.5 for all datasets, K-means initialisation for the shared factor matrices (F t) and
least squares for the private ones (Gl,Sn).
The results are given in Table 14, where the left three columns indicate the factorisation
37
Table 13: Spearman correlation between values of each of the dataset pairs.
GE GM PM
GE - -0.07 -0.12
GM -0.07 - 0.14
PM -0.12 0.14 -
Table 14: Performances of out-of-matrix cross-validation results on the methylation datasets, where we vary
the factorisation types on each of the three datasets. The best performances are highlighted in bold.
Factorisation type Performance
GE GM PM GE GM PM
R R R 0.876 0.744 0.864
D R R 0.877 0.717 0.949
R D R 1.128 0.698 0.960
R R D 0.860 0.692 0.834
D D D 0.869 0.663 0.799
types, and the right three give the predictive performances on each of the datasets (each
column corresponds to an experiment where we predict missing rows in that dataset). As can
be seen, using multiple matrix factorisation (D for all matrices) gives the best performance
most of the time, which is unsurprising since the three datasets are so weakly correlated. The
best performance for GE (R,R,D) is most likely due to random variations of performance in
the cross-validation procedure (the splitting of data into train and test sets is done randomly
each time).
Drug sensitivity data
Similarly, we do this experiment for the four drug sensitivity datasets, for in-matrix predic-
tions. These four datasets have much higher correlation (as they are repeated experiments –
the same experiment conducted by different biological labs), as shown in Table 15, giving the
Spearman correlation between the overlapping observed entries in each pair of the datasets.
You can also find the overlaps between the datasets in Table 16, from the main paper. Here
we see that:
• CCLE IC50 and CCLE EC50 are highly correlated, and have a big overlap.
• GDSC IC50 and CCLE IC50 are highly correlated, but few GDSC entries are also in
CCLE. In contrast, many CCLE entries are in GDSC.
• GDSC IC50 and CCLE EC50 are (relatively) weakly correlated, but have a very small
overlap. Overlap wise the same applies as for CCLE IC50.
• Very few CTRP EC50 entries are in CCLE IC50 or EC50, but many are in GDSC IC50.
For the experiments we used Kt = 10 and α = 1.0 for all datasets, K-means initialisation
for the shared factor matrices (F t) and least squares for the private ones (Gl,Sn, and if we
used matrix factorisation we shared the row factors (corresponding to drugs). The results
are given in Table 17. There are a lot of results, so we will consider them one column at a
time.
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Table 15: Spearman correlation between values of each of the dataset pairs.
GDSC IC50 CTRP EC50 CCLE IC50 CCLE EC50
GDSC IC50 - 0.47 0.59 0.39
CTRP EC50 0.47 - 0.44 0.45
CCLE IC50 0.59 0.44 - 0.65
CCLE EC50 0.39 0.45 0.65 -
Table 16: Overview of the four drug sensitivity dataset after preprocessing and filtering.
Number Number Fraction Overlap with other datasets
Dataset cell lines drugs observed GDSC IC50 CTRP EC50 CCLE IC50 CCLE EC50
GDSC IC50 399 48 73.57% - 52.25% 9.34% 6.00%
CTRP EC50 379 46 86.03% 57.39% - 11.96% 7.37%
CCLE IC50 253 16 96.42% 44.19% 51.51% - 55.06%
CCLE EC50 252 16 58.88% 28.52% 31.87% 55.28% -
Table 17: Performances of in-matrix cross-validation results on the drug sensitivity datasets, where we vary
the factorisation types on each of the four datasets. The best performances are highlighted in bold.
Factorisation type Performance
GDSC IC50 CTRP EC50 CCLE IC50 CCLE EC50 GDSC IC50 CTRP EC50 CCLE IC50 CCLE EC50
R R R R 0.0767 0.0889 0.0537 0.1071
D R R R 0.0765 0.0901 0.0546 0.1098
R D R R 0.0758 0.0909 0.0543 0.1079
R R D R 0.0765 0.0890 0.0584 0.1055
R R R D 0.0768 0.0893 0.0537 0.1078
D D R R 0.0763 0.0899 0.0569 0.1079
D R D R 0.0766 0.0901 0.0553 0.1090
D R R D 0.0769 0.0898 0.0554 0.1064
R D D R 0.0765 0.0901 0.0566 0.1060
R D R D 0.0772 0.0906 0.0543 0.1082
R R D D 0.0771 0.0892 0.0542 0.1076
D D D D 0.0776 0.0910 0.0562 0.1064
• GDSC IC50 (first column) – multiple matrix tri-factorisation (first row) achieves better
performance than multiple matrix factorisation (last row), but a slight improvement can
be achieved using a hybrid approach.
• CTRP EC50 (second column) – the best performance is achieved when using multiple
matrix tri-factorisation on all datasets. Note that the CTRP dataset has a very similar
correlation to all three other datasets.
• CCLE IC50 (third column) – the best performance is achieved when using multiple
matrix tri-factorisation on all datasets, or when only CCLE EC50 is not decomposed as
an R matrix, but using matrix factorisation (D) instead.
• CCLE EC50 (last column) – the best performances are achieved when the CCLE
IC50 and EC50 are not both decomposed as an R matrix, but instead one or either is
decomposed as a D matrix.
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The last two items seem to imply that having a large overlap of entries and high corre-
lation (such as CCLE IC50 and EC50), does not necessarily mean we should use matrix
tri-factorisation on both datasets. The best hybrid combination of factorisations is not so
obvious, but by trying out multiple candidates a suitable hybridity can be found.
Recommendation For dissimilar datasets, with low correlation (like the methylation data),
it is best to use multiple matrix factorisation. When the datasets are very similar, with high
correlation (like the drug sensitivity data), matrix tri-factorisation can give better results.
These two models will generally give very good performance already. One of the hybrid
combinations of matrix factorisation and tri-factorisation can sometimes lead to even better
results. Nested cross-validation can be used to find the best hybrid combination.
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